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ABSTRACT 
 
PREDICTION OF PROAPOPTOTIC ANTICANCER THERAPEUTIC 
RESPONSE BASED ON VISUALIZATION OF DEATH LIGAND-RECEPTOR 
INTERACTION AND SPECIFIC MARKER OF CELLULAR PROLIFERATION 
 
Lanlan Zhou 
Supervisor: Wafik S. El-Deiry, M.D. Ph.D. 
 
Emerging targeted therapeutics hold great promise for the treatment of human cancer. 
However there are still challenges for selecting patients that most likely will benefit from 
targeted drugs. One of the major limitations of classical imaging methods is the 
significant delay to provide quantifiable and objective evidence of response to cancer 
therapy. Molecular imaging may be useful in targeted drug development by assessing the 
target expression and drug-target interaction, and predicting therapeutic response in both 
preclinical and clinical settings. The apoptosis pathway triggered by the Tumor Necrosis 
Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) receptors is a potential target 
for therapeutic intervention. TRAIL and its proapoptotic receptor agonistic monoclonal 
antibodies are being developed as targeted therapeutics in the treatment of human cancer. 
It is our hypothesis that visualization of proapoptotic receptors and binding of their 
agonists to proapoptotic receptors can noninvasively predict proapoptotic response if the 
pathway is intact. Hence the objective of this work is to develop efficient multimodality 
molecular imaging methods to predict proapoptotic anticancer therapy response before or 
vii 
at the very early stage of treatment. Towards this goal, we have labeled proapoptotic 
receptor agonists (PARAs) with near-infrared (NIR) fluorescent dyes to image PARAs 
binding to their targets expressed on the cell surface in cultured cells and in human tumor 
xenografts grown subcutaneously in immunodeficient mice. Both in vitro and in vivo 
studies demonstrated that imaging PARAs binding to their targets was well correlated 
with proapoptotic anticancer therapeutic response when TRAIL signaling pathway was 
intact.  To pursue a more general molecular imaging marker that can predict anticancer 
therapeutic response even when the signaling pathway is impaired, we explored a novel 
radiotracer for positron emission tomography (PET) imaging 18F-3'-fluoro-3'-deoxy-L-
thymidine (18F-FLT), an analogue of thymidine and a specific marker of DNA replication 
and cellular proliferation. Our results suggested that early changes in 18F-FLT-PET may 
not only predict the tumor histological response to anticancer therapeutics but also 
determine superiority of one treatment regimen over another. In summary our proof-of-
concept studies show that multimodality molecular imaging will greatly aid in 
accelerating anticancer drug approval process and improving survival and response rates 
in hard-to-treat cancer. 
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CHAPTER 1 
Introduction 
1.1 Cancer and apoptosis 
Cancer is the second most common cause of death in the US (American Cancer Society 
2010). The 5-year relative survival rate for all cancers diagnosed between 1995 and 2001 
was 65% (Parkin, Bray et al. 2005). Insufficient apoptosis can result in cancer. Apoptosis, 
an evolutionarily conserved mechanism of programmed cell death mediated principally 
by caspases, plays a crucial role in successful embryonic development and maintains 
normal cellular homeostasis in adult organisms (Kerr, Wyllie et al. 1972). The 
proapoptotic caspase cascade acts as the principal executioner in apoptosis - the initiators 
(caspases 2, 8, 9, and 10) activate the effectors (caspases 3, 6, and 7) to execute apoptosis. 
Cells undergo apoptosis through two separate but interlinked signaling mechanisms: the 
extrinsic pathway, activated by proapoptotic receptor signals at the cellular surface, and 
the intrinsic pathway, activated by mitochondrial signals within the cell. They converge 
through effector caspases (Lavrik, Golks et al. 2005).  
The extrinsic pathway is initiated by members of the tumor necrosis factor (TNF) 
superfamily as described in the section of the tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) signaling. The intrinsic pathway triggers apoptosis in response 
to loss of survival factors or severe cell stresses such as DNA damage. The intrinsic 
pathway involves the activation of the proapoptotic Bcl-2 proteins and the release of 
apoptogenic factors such as cytochrome c and SMAC/DIABLO from the mitochondria 
into the cytosol (Adams and Cory 1998; Green 2000; Hunt and Evan 2001). In the 
cytosol, cytochrome c binds the adaptor apoptotic protease-activating factor 1 (APAF-1) 
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and the initiator caspase 9 to form the multimeric apoptosome (a complex comprising 
APAF-1, deoxyadenosine triphosphate (dATP), cytochrome c and caspase 9) to activate 
the initiator caspase-9. In turn, caspase-9 activates effector caspase-3, -6, and -7. 
SMAC/DIABLO promotes apoptosis by binding to inhibitor of apoptosis proteins (IAP) 
and preventing these factors from attenuating caspase activation (Du, Fang et al. 2000; 
Verhagen, Ekert et al. 2000). The intrinsic and extrinsic apoptosis signaling pathways 
communicate with each other. Caspase-8 has been shown to cleave the proapoptotic Bcl-
2 family member Bid. The cleavage of Bid by caspase-8 and the translocation of 
truncated Bid to the mitochondria to promote cytochrome c release through interaction 
with Bax and Bak provide a plausible mechanistic link between the extrinsic and intrinsic 
pathways (Green 2000). This apparently amplifies the apoptotic signal following death 
receptor activation, and different cell types may be more reliant on this amplification 
pathway than others (Fulda, Meyer et al. 2001). Thereby activators of the intrinsic 
pathway can sensitize cells to extrinsic death ligands. 
1.2 TRAIL signaling 
TRAIL is a TNF family member. It is also designated as Apo-2 ligand (Apo-2L) because 
it is related most closely to Fas/Apo-1 ligand. TRAIL consists of 281 and 291 amino 
acids (AA) in the human and murine forms respectively with 65% AA identity. TRAIL is 
expressed at the cell surface with its carboxyl terminus exposed, indicating a type II 
transmembrane protein topology. The C-terminal extracellular region of TRAIL, AA 
114-281, exhibits clear homology to other TNF family members, and is processed 
proteolytically to form a soluble homotrimeric molecule (Wiley, Schooley et al. 1995; 
Pitti, Marsters et al. 1996). The TRAIL gene is located on chromosome 3 at position 3q26 
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(Wiley, Schooley et al. 1995). The biological role of TRAIL is not fully understood yet. 
While TRAIL mRNA is constitutively expressed in a wide variety of normal tissues, 
most predominantly in spleen, lung and prostate, the expression of functional TRAIL 
protein appears to be rather restricted to immune cells, including T cells, NK cells, 
monocytes, dendritic cells and neutrophils. TRAIL plays important roles in inflammation, 
the immune response and tumor surveillance (Ashkenazi and Dixit 1999). TRAIL 
receptor deficient mice showed that metastasis to lymph nodes was significantly 
enhanced, indicating that TRAIL-R could inhibit metastasis. The possible mechanism is 
that detachment from the primary tumor can sensitize resistant TRAIL-R-expressing 
cancer cells to TRAIL (Grosse-Wilde, Voloshanenko et al. 2008). 
Both full-length cell surface expressed TRAIL and picomolar concentrations of 
recombinant soluble TRAIL (rsTRAIL) rapidly induce apoptosis in a wide variety of 
transformed cell lines of diverse origin (Wiley, Schooley et al. 1995; Pitti, Marsters et al. 
1996). Unlike conventional cancer therapeutics, TRAIL triggers tumor cell apoptosis 
independently of the p53 tumor suppressor gene, which frequently is inactivated in 
cancer. TRAIL offers promising therapeutic potential based on its ability to induce 
apoptosis in various cancer cell lines with little toxicity toward normal cells. Moreover, 
TRAIL displays single-agent activity and cooperates with chemotherapy or radiotherapy 
in a variety of tumor xenograft mouse models. Thus, TRAIL might be effective against 
tumors that have acquired resistance to conventional therapy, and could augment the 
efficacy of current treatment in a wide spectrum of cancers (Kelley and Ashkenazi 2004). 
The clinical utility of TNF and Fas has been hampered by toxicity to normal tissues. 
Intravenous TNF administration causes hypotension and a systemic inflammatory 
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syndrome that resembles septic shock due to strong activation of pro-inflammatory 
nuclear factor -B (NF-B). Injection of agonist anti-Fas antibodies induces hepatocyte 
apoptosis and lethal hepatic failure in mice (Feinberg, Kurzrock et al. 1988; Ogasawara, 
Watanabe-Fukunaga et al. 1993; Lejeune, Kroon et al. 2001; Hochedlinger, Wagner et al. 
2002). TRAIL is still considered a promising anticancer agent due to a more acceptable 
toxicity profile. In preclinical models, it induces apoptosis in a wide range of tumor cells 
and xenografts, without causing toxicity to normal cells (Ashkenazi 2002). A 
combination treatment of TRAIL with ionizing irradiation or chemotherapeutic agents 
induces apoptosis in a highly synergistic manner, particularly in those cells that are 
otherwise resistant to the individual treatments. Furthermore, in contrast to its structural 
and functional homologues TNF and Fas-L, systemic exposure to TRAIL does not exert 
overt systemic toxicity in murine and primate models although concerns about a potential 
hepatotoxicity associated with nonoptimized preparations of TRAIL have been raised 
(Held and Schulze-Osthoff 2001; Kelley and Ashkenazi 2004; Ashkenazi, Holland et al. 
2008). Currently, rsTRAIL is in clinical trials as a selective killer of tumor cells either 
alone or in combination with chemotherapeutic drugs.  
Five distinct TRAIL receptors have been identified: DR4 (TRAIL-R1) (Pan, O'Rourke et 
al. 1997), DR5 (TRAIL-R2) (Walczak, Degli-Esposti et al. 1997; Wu, Burns et al. 1997), 
DcR1 (TRAIL-R3) (Sheridan, Marsters et al. 1997), DcR2 (TRAIL-R4) (Pan, Ni et al. 
1997) and Osteoprotegerin (OPG) (Emery, McDonnell et al. 1998). TRAIL receptors 
have been localized to human chromosome 8p21-22 (Walczak, Degli-Esposti et al. 1997; 
Ashkenazi and Dixit 1998). All these receptors have high sequence homology in their 
extracellular domains (Lee, Lee et al. 2005). They can be classified into two groups, 
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proapoptotic receptors (DR4 and DR5) and antiapoptotic receptors (DcR1, DcR2 and 
OPG) (LeBlanc and Ashkenazi 2003). DR4/5 is a type I membrane protein of 468/440 
AA, containing two extracellular cysteine-rich pseudo-repeats and an intracellular death 
domain (DD) similar to the one of TNF-R1, DR3, Fas and CAR1 within the 
cytoplasmatic domain. DR5 has a homology of 58% with DR4. Both DR4 and DR5 
contain a conserved DD motif and signal apoptosis (Pan, O'Rourke et al. 1997; Walczak, 
Degli-Esposti et al. 1997; Wu, Burns et al. 1997). The other three receptors appear to act 
as 'decoys' for their ability to inhibit TRAIL-induced apoptosis when overexpressed. 
DcR2 has a truncated, nonfunctional cytoplasmic DD while DcR1 lacks a cytosolic 
region and is anchored to the plasma membrane through a glycophospholipid moiety (Pan, 
Ni et al. 1997; Sheridan, Marsters et al. 1997). OPG binds TRAIL but has lower affinity 
at physiological temperature (Emery, McDonnell et al. 1998). A recent study suggests 
that cancer-derived OPG may be an important survival factor in hormone-resistant 
prostate cancer cells and there is a negative correlation between the levels of OPG and 
the capacity of TRAIL to induce apoptosis in prostate cancer cells that endogenously 
produce a high level of OPG (Holen, Croucher et al. 2002). In mice, there is only one 
death-inducing receptor for TRAIL, a protein homologous to human DR5 (mTRAIL-R, 
mDR5) (Wu, Burns et al. 1999).  
As shown in Figure 1.1, binding of TRAIL to its proapoptotic receptors DR4 and DR5 
triggers trimerisation of the receptors and formation of the death-inducing signaling 
complex (DISC) by recruiting the adaptor molecule Fas-associated death domain 
(FADD), initiator caspase-8 and 10, followed by activation of caspase-8 and 10 and in 
turn caspase-3 which directly triggers a caspase cascade leading to apoptosis. Caspase-8 
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and 10 activation at the DISC can be inhibited by the cellular FLICE-inhibitory protein 
(cFLIP, FLICE is the old name of caspase 8) short form (cFLIPS) and high levels of long 
form (cFLIPL) which has two death effector domains (DEDs) similar to caspase-8 and 10 
but be promoted by low levels of cFLIPL (Chang, Xing et al. 2002; Yang 2002). Based on 
the requirement of the intrinsic pathway for apoptosis mediated by death receptors, cells 
can be divided into two types (Ozoren and El-Deiry 2002; Barnhart, Alappat et al. 2003). 
In type I cells, activation of caspase-8 in the DISC is sufficient to induce apoptosis. 
Peripheral T cells and thymocytes, human non small cell lung cancer cell line H460, 
human colon cancer cell line SW480 and HT29, human B lymphoblastoid cell line 
SKW6.4, human T lymphoma cell line HuT78, human Burkitt's lymphoma cell line 
BJAB and Raji, human hepatocellular carcinoma cell line HepG2, and human T 
lymphocyte H9 are type I cells (Scaffidi, Fulda et al. 1998; Scaffidi, Schmitz et al. 1999; 
Ozoren and El-Deiry 2002; Barnhart, Alappat et al. 2003). However, in type II cells, only 
a small amount of FADD and caspase-8 are recruited to the DISC, so insufficient 
activation of caspase-8 requires further amplification of the signal for apoptosis 
activation. This occurs through caspase 8-dependent cleavage of the BH3-only protein 
Bid, which then engages the intrinsic pathway to produce greater effector caspase activity 
(Scaffidi, Fulda et al. 1998). Hepatocytes, human esophageal cells, Lymphoblast CEM, T 
leukaemia cell line Jurkat, pre-B-cell line BoeR, human epithelial adenocarcinoma cells 
HeLa, human colon cancer cell line HCT116 are type II cells (Scaffidi, Fulda et al. 1998; 
Scaffidi, Schmitz et al. 1999; Ozoren and El-Deiry 2002; Barnhart, Alappat et al. 2003). 
TRAIL-induced apoptosis also involves the intrinsic pathway in type II cells. Release of 
Smac/Diablo from mitochondria to block the caspase-3 inhibitory effect of the X 
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chromosome-linked inhibitor of apoptosis proteins (XIAP) is required for type II cells to 
undergo apoptosis in response to TRAIL. Blockade of the intrinsic pathway by 
overexpression of antiapoptotic Bcl-2 proteins such as Bcl-2 and Bcl-XL or inactivation 
of Bax may change TRAIL sensitivity in type II cells (Ozoren and El-Deiry 2002). A 
recent long-term clonogenicity study suggests that the mitochondrial pathway is essential 
for apoptotic execution of Type I tumor cells by death receptors: the release of 
Smac/DIABLO and the inhibition of XIAP activity proved to be crucial for full effector 
caspase activity and clonogenic execution in Type I tumor cells (Maas, Verbrugge et al. 
2010). 
1.3 TRAIL proapoptotic receptor-targeted therapy 
Conventional chemotherapy kills rapidly dividing cells including both tumor and normal 
cells causing side effects like hair loss, nausea, diarrhea and anemia. But targeted 
therapies aim at tumor growth or survival associated proteins that ideally are not found in 
healthy cells. Hence targeted therapies can improve treatment response but with fewer 
side effects, which accelerates the pace toward personalized therapy. The apoptosis 
pathway triggered by the TRAIL proapoptotic receptors DR4/5 is a potential target for 
anticancer therapeutic intervention. Promoting apoptosis specifically in tumor cells via 
activation of DR4/5 has generated some of the most advanced and promising cancer 
therapies in development. As summarized in Table 1.1, current proapoptotic receptor 
agonist (PARA) approaches include dual activation of the proapoptotic receptors DR4 
and DR5 with recombinant human TRAIL (rhTRAIL) and several single receptor-
targeting agonistic monoclonal antibodies such as HGS-ETR1 (Mapatumumab, TRM-1) 
and HGS-ETR2 (Lexatumumab, TRM-2) developed by Human Genome Sciences 
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(Ashkenazi and Herbst 2008). There are 25 ongoing clinical trials targeting TRAIL 
proapoptotic receptors (Russo, Mupo et al. 2010). Combining knowledge on the TRAIL 
signaling pathway with PARA clinical response data and tumor characteristics may give 
rise to true tumor-tailored therapy. 
Soluble rhTRAIL is unique in that it activates both DR4 and DR5. Preclinical data 
indicate that rhTRAIL can induce apoptosis in a broad range of human cancer cell lines 
while sparing most normal cell types. RhTRAIL exhibits single-agent antitumor activity 
and/or cooperation with certain conventional and targeted therapies in vitro and in various 
in vivo tumor xenograft models. Safety studies in nonhuman primates have shown 
rhTRAIL to be well tolerated. After a single intravenous (IV) bolus administration, 
rhTRAIL exhibited a serum half-life (t1/2) of approximately 3 to 5 minutes in rodents and 
approximately 23 to 31 minutes in primates. It is primarily eliminated through the 
kidneys (Duiker, Mom et al. 2006). Despite a very short t1/2 of rhTRAIL in mouse and the 
estimated steady-state volumes of distribution indicating that rhTRAIL may not distribute 
greatly outside of the vascular space prior to its elimination from the system, rhTRAIL 
has demonstrated significant antitumor activity in mice containing human xenografts 
(Kelley, Harris et al. 2001). Rapid clearance was observed after a 1-hour IV infusion of 
rhTRAIL at 10~100 mg/kg in cynomolgus monkeys, with a serum t1/2 of 28 to 30 minutes 
after infusion of the highest dose. The pharmacokinetics (PK) studies suggest a dose-
dependent profile that does not lead to accumulation over time. The relatively short serum 
t1/2 may require frequent administration. Further optimization of dose and regimen has 
been under investigation (Ashkenazi, Holland et al. 2008). In chimpanzees, clearance was 
linear over the dose range 1~ 50 mg/kg and the area under the curve (AUC) of serum 
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drug concentration versus time and the maximal serum concentration (Cmax) increased 
proportionally with dose (Kelley, Harris et al. 2001).  A preclinical study demonstrated 
that cisplatin can sensitize resistant primary human hepatocytes to TRAIL (Ganten, 
Koschny et al. 2006). Moreover early clinical trial data suggest that rhTRAIL is generally 
safe and provide preliminary evidence for potential antitumor activity. A current clinical 
experimental treatment schedule is 1-hour rhTRAIL infusion for 5 days every 3 weeks. A 
phase Ia safety and PK study was conducted in patients with various advanced solid 
tumors or Non-Hodgkin lymphoma (NHL). RhTRAIL proved to be safe and well 
tolerated at dose 0.5~15 mg/kg in 58 patients with no drug-related dose-limiting toxicities 
(DLT) observed. Single-agent rhTRAIL up to 8 cycles yielded stable disease (SD) in 21 
of 37 heavily pretreated patients who were assessable for response, and a validated partial 
response (PR) in one patient. Among reported 46 patients, rhTRAIL exhibited a linear PK 
profile consistent with preclinical studies. Hepatic metastases with or without mild liver 
dysfunction did not appear to influence the PK of TRAIL (Herbst, Mendelson et al. 2006; 
Ling, Herbst et al. 2006). The first reported single agent phase I, open-label, dose-
escalation study treated patients with advanced cancer with rhApo2L/TRAIL doses 
ranging from 0.5 to 30 mg/kg/d with parallel dose escalation, given daily for 5 days every 
3 weeks. RhApo2L/TRAIL was safe and well tolerated. Overall 33 (46%) of 71 patients 
had stable disease or better at the end of cycle 2. Eight patients had stable disease for > 4 
months but < 6 months. Two patients (3%) with chondrosarcoma had confirmed partial 
responses at > 6 months  (Herbst, Eckhardt et al. 2010). The first reported phase Ib study 
treataed 24 previously untreated, nonsquamous, stage IIIb (with pleural effusion)/IV or 
recurrent non–small-cell lung cancer (NSCLC) with rhApo2L/TRAIL at 4 or 8 mg/kg/d 
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for 5 consecutive days or 15 or 20 mg/kg/d for 2 consecutive days every 3 weeks in 
combination with paclitaxel, carboplatin, and bevacizumab. The drug combination was 
well tolerated and demonstrated antitumor activity - one confirmed complete response 
and 13 confirmed partial responses (Soria, Smit et al. 2010). Phase II clinical trials 
evaluating the safety and efficacy of rhTRAIL in combination with established anticancer 
therapies are ongoing.  
HGS-ETR1 and HGS-ETR2 are fully humanized agonistic monoclonal antibodies to DR4 
and DR5. The advantages of the agonistic antibodies compared with TRAIL include a 
longer plasma t1/2 and the lack of binding to decoy receptors (Buchsbaum, Forero-Torres 
et al. 2007). Pretreatment with cisplatin followed by HGS-ETR1 or HGS-ETR2 
synergistically inhibited the cell growth and enhanced apoptotic death (Belyanskaya, 
Marti et al. 2007). 
HGS-ETR1 reduced the viability of multiple types of tumor cells in vitro, and induced 
activation of caspase 8, Bid, caspase 9, caspase 3, and cleavage of the poly (ADP-ribose) 
polymerase (PARP), indicating activation of DR4 alone was sufficient to induce both 
extrinsic and intrinsic apoptotic pathways. HGS-ETR1 enhanced the cytotoxicity of 
chemotherapeutic agents even in tumor cell lines that were not sensitive to HGS-ETR1 
alone. In xenograft models, HGS-ETR1 induced rapid tumor regression or repression of 
tumor growth in a broad range of tumors. Combination of HGS-ETR1 with 
chemotherapeutic agents resulted in an enhanced antitumor efficacy compared to either 
agent alone (Pukac, Kanakaraj et al. 2005). Sequential treatment with paclitaxel followed 
by HGS-ETR1 or HGS-ETR2 after 48 h resulted in markedly enhanced antitumor activity 
against Colo205 mouse xenografts (Gong, Yang et al. 2006). Preclinical studies suggest 
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that HGS-ETR1 is a specific and potent antitumor agent with favorable PK characteristics 
and the potential to provide therapeutic benefit for a broad range of human malignancies 
(Pukac, Kanakaraj et al. 2005). A phase I safety, PK, and preliminary evidence of 
antitumor activity study in patients with advanced solid malignancies showed that HGS-
ETR1 can be administered safely and feasibly at 10 mg/kg IV every 14 days, with t1/2 of 
18.8 days and mild adverse events. In a total of 49 patients, 19 patients had stable disease 
(SD) with two responses in patients lasting 9 months. Further disease-directed studies of 
HGS-ETR1 alone and in combination with chemotherapy in a broad array of tumors are 
warranted (Tolcher, Mita et al. 2007). A phase I open-label, dose-escalation study 
assessed the tolerability and toxicity profile in 41 patients with advanced solid tumors 
showed that HGS-ETR1 was well tolerated with escalation levels from 0.01 to 20.0 
mg/kg. The maximum tolerated dose was not reached. Linear pharmacokinetics was 
observed for doses up to 0.3 mg/kg and for the 20 mg/kg level, whereas exposure at 3 and 
10 mg/kg increased less than proportionally. 12 patients had SD for 1.9 to 29.4 months 
(Hotte, Hirte et al. 2008). A phase II multi-center study in 32 patients with advanced 
heavily pretreated NSCLC showed HGS-ETR1 was safe and well tolerated at 10mg/kg 
IV every 21 days. 9 patients (29%) had SD (Greco, Bonomi et al. 2008). Phase II and 
Phase Ib combination studies of HGS-ETR1 to evaluate its potential for the treatment of 
specific cancers have been initiated. 
HGS-ETR2 has shown broad and significant activity across a broad range of cell lines in 
vitro and in vivo as a single agent and in combination with chemotherapy. A phase I 
dose-escalation safety, tolerability and PK study in patients with advanced solid 
malignancies showed HGS-ETR2 can be safely administered every 14 days at doses up to 
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10.0 mg/kg. In 31 patients, one patient experienced a dose-limiting toxicity (DLT) (grade 
3 hyperamylasemia) at the 10 mg/kg dose level, 10 patients (32.3%) had SD. HGS-ETR2 
PK is linear up to 10 mg/kg. At the 10 mg/kg dose, the t1/2 was found to be 11 days. The 
large steady-state volume of distribution indicates that HGS-ETR2 distributes outside the 
plasma compartment (Sarantopoulos, Wakelee et al. 2005; Manzo, Nebbioso et al. 2009). 
A phase I open label study in patients with advanced solid malignancies showed that the 
PK was linear over the dose range of 0.1~ 20 mg/kg, DLT (asymptomatic elevations of 
serum amylase, transaminases, and bilirubin) dose is 20 mg/kg, the maximum tolerated 
dose is 10 mg/kg, t1/2 at the 10 mg/kg IV every 21 days is 16.4 days. In 37 patients, 12 
patients had durable SD. HGS-ETR2 was safe and well tolerated at doses 10 mg/kg 
every 21 days (Plummer, Attard et al. 2007). A phase Ib HGS-ERT2 in combination with 
chemotherapy study in 41 patients with a wide range of solid malignancies demonstrated 
that HGS-ETR2 at 5 mg/kg or 10 mg/kg was generally safe and well tolerated in 
combination with full-dose different standard chemotherapy regimens. Objective 
responses were reported for two patients and 22 patients had SD. The PK of HGS-ETR2 
was not influenced by the chemotherapeutic agents and vice versa. Further studies of 
HGS-ETR2 in combination with chemotherapy are warranted (Sikic, Wakelee et al. 
2007).  
1.4 Sorafenib 
The well-tolerated targeted agents provide new options for the combination treatment of 
patients with advanced solid tumors. The RAF/MEK/ERK pathway and upregulation of 
VEGFR both play important roles in the growth and maintenance of solid tumors. Thus 
blocking these signaling pathways will be another promising target for cancer therapy. 
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The novel bi-aryl urea Sorafenib (Nexavar®; Bayer Pharmaceuticals Corporation, Onyx 
Pharmaceuticals) is an oral multi-kinase inhibitor with novel dual action Raf 
serine/threonine kinases (Raf-1, wild-type B-Raf, and b-raf V600E) and receptor tyrosine 
kinases (the vascular endothelial growth factor receptor (VEGFR)-1/-2/-3, platelet-
derived growth factor receptor-β (PDGFR-β) and Flt-3, c-Kit, and p38 tyrosine kinases) 
inhibition that targets tumor cell proliferation and tumor angiogenesis (Wilhelm, Carter et 
al. 2004). The mechanism of action of Sorafenib is competitive inhibition of ATP-
binding to the catalytic domains of the respective kinases (Wilhelm and Chien 2002; 
Huether, Hopfner et al. 2007). Targeting multiple pathways makes Sorafenib more 
favorable since cancer may be altering multiple targets. Sorafenib is generally well 
tolerated and synergizes with many standard chemotherapy agents and cytotoxic agents, 
and has shown promise in a variety of malignancies including gastrointestinal 
malignancies, renal cell carcinoma, hepatocellular carcinoma and lung cancer (Vincent, 
Zhang et al. 2002; Heim, Sharifi et al. 2003). Sorafenib has demonstrated preclinical and 
clinical anticancer activity as a monotherapy and in combination with other anticancer 
agents. Proven effective as a single-agent therapy in renal cell carcinoma, Sorafenib was 
approved in the U.S. in December 2005 (Dal Lago, D'Hondt et al. 2008). Sorafenib is the 
first approved systemic drug therapy for unresectable hepatocellular carcinoma (HCC), as 
well as being the only medication therapy proven to significantly improve overall 
survival in HCC patients (http://www.cancer.gov/cancertopics/druginfo/fda-Sorafenib-
tosylate). The safety, PK, and anti-tumor activity of Sorafenib combined with other 
targeted agents or cytotoxics from Phase I/II trials were reviewed by Takimoto (Takimoto 
and Awada 2008). In brief the recommended dose of Sorafenib for combination is 400 
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mg twice daily. Sorafenib was well tolerated with mild adverse events and had little 
effect on the PK of coadministered agents and vice versa. Overall disease control rates 
(PR plus SD) ranged from 33 to 92% (Takimoto and Awada 2008). The antiproliferative 
and antiangiogenic mechanisms of Sorafenib in combination with other anticancer agents 
with complementary or contrasting mechanisms such as PARAs are potentially valuable 
new treatment regimens for patients with advanced solid tumors. The combination 
therapy of Sorafenib and TRAIL appears to be rational, much less toxic, and dramatically 
effective on TRAIL-resistant tumors in preclinical trials. The synergistic effects of 
combining Sorafenib with TRAIL include sensitization to TRAIL induced apoptosis, 
inhibiting tumor growth, reducing levels of TRAIL induced antiapoptotic factors such as 
Mcl-1 Bcl-XL and cIAP2, and increasing proapoptotic factors Bak, Bid and Bax 
activation (Meng, Lee et al. 2007; Ricci, Kim et al. 2007; Rosato, Almenara et al. 2007). 
Currently there is an ongoing clinical trial “A Study of Mapatumumab in Combination 
With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)”. 
1.5 Molecular imaging in cancer therapy response prediction 
Predicting tumor responsiveness to treatment at an early phase would be very useful to 
identify responders and avoid prolonged use of ineffective therapies. A variety of routine 
anatomical imaging modalities are used to evaluate treatment efficacy. However changes 
in tumor physiology, proliferation and metabolism often precede these volumetric 
changes. Therefore imaging these early changes will help to assess or even predict 
treatment response (Verheij 2008). Molecular imaging can be used to find out early 
whether an agent is having a measurable effect on a biological endpoint. To predict 
therapy response using molecular imaging, the most straightforward approach is direct 
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visualization of target and ligand-target binding using labeled ligands. Nuclear imaging 
and in particular positron emission tomography (PET) have been used to study receptor 
occupancy. In studies related to PARAs, radiolabeled receptor antibodies were used to 
assess receptor expression level and receptor occupancy with gamma camera and PET 
respectively (Gong, Yang et al. 2006; Hwang, Rossin et al. 2008). Optical-based 
molecular imaging is an emerging field with the advantages of cost-effective, rapid, easy 
to use, and ready for in vivo studies. Optical molecular imaging plays an important role in 
oncologic drug development in both preclinical and clinical settings. Light in the near 
infrared (NIR) range (650–900 nm) can traverse tissue very efficiently as the absorption 
by water and endogenous chromophores such as hemoglobin, melanin, and lipids is 
relatively low in this spectrum. Tissue autofluorescence is minimal at 800 nm. So an 
optimal wavelength for imaging is centered at 800 nm. Indocyanine green (ICG) has been 
used as the only FDA approved NIR dye for clinical retinal angiography. But ICG does 
not have a reactive group for conjugation to a targeting moiety for molecular imaging. 
ICG is hydrophobic and is bound nonspecifically to serum proteins. The excitation and 
emission of IRDye 800CW (LI-COR Biosciences) is in the spectral region where tissue 
absorption, autofluorescence, and scattering are minimal yielding the highest signal to 
background ratios. By contrast, IRDye 800CW reactive dyes can be easily conjugated to 
a variety of targeting agents. IRDye 800CW is highly water soluble and shows very low 
nonspecific binding to cellular components and yields very high signal. In animal studies, 
it has been shown to clear through the kidneys and is approximately twenty times brighter 
than ICG. Recently a single-dose intravenous toxicity study of IRDye 800CW was 
performed. Intravenous dose levels of 1, 5, and 20 mg/kg or intradermal 20 mg/kg 
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produced no pathological evidence of toxicity (Marshall, Draney et al. 2010). Targeting 
agents such as small polypeptide growth factors, monoclonal antibodies, peptide 
analogues of extracellular ligands endostatin and somatostatin, labeled with Cy5.5, Alexa 
Fluor® 680, or IRDye 800CW, have been used successfully for optical noninvasive 
detection of tumor xenografts in mice. EGF labeled with Cy5.5 was used to quantify 
therapeutic efficacy of anti-EGF receptor antibodies for treating mammary carcinoma in 
mice (Kovar, Johnson et al. 2006; Kovar, Volcheck et al. 2007). 
The presence of DR4 and DR5 on the tumor cell surface is a necessary but not always 
sufficient prerequisite for antitumor activity induced by PARAs. Efficacy biomarkers 
targeting general tumor properties such as proliferation, angiogenesis and apoptosis of 
tumors are therefore exploited. Increased cellular proliferation is a hallmark of the cancer. 
Thymidine kinase activity increases about 10-fold as cells enter the DNA synthetic phase 
(Choy, Choyke et al. 2003). Cell proliferation imaging assesses the uptake and 
metabolism of nucleosides used in nucleic acid synthesis. Monophosphorylation of the 
thymidine nucleoside analogue 3'-[18F]fluoro-3'-deoxy-L-thymidine (18F-FLT) by 
intracellular thymidine kinase-1 (TK-1) results in FLT trapping in proliferating cells. FLT 
images reflect TK-1 activity and the percentage of cells in S phase (Rasey, Grierson et al. 
2002). PET is emission computed tomography that is used to study the distribution of 
radiolabeled tracers within the body. PET radiotracers emit positrons that, after 
encountering electrons, lead to emission of 2 gamma rays directed at 180 degrees from 
each other. Sites of tracer accumulation in the body are thus determined by coincidence 
detection of these paired gamma rays. FLT-PET is thus used to measure cellular TK-1 
activity and thereby infer the rate of cellular proliferation. Treatment response was 
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predicted by tumor FLT uptake changes in as early as 24 hours after the initiation of 
treatment (Barthel, Cleij et al. 2003; Sugiyama, Sakahara et al. 2004; Waldherr, 
Mellinghoff et al. 2005; Apisarnthanarax, Alauddin et al. 2006; Chao 2006; Yang, Ryu et 
al. 2006; Buck, Kratochwil et al. 2007; Chen, Delaloye et al. 2007; Herrmann, Wieder et 
al. 2007; Molthoff, Klabbers et al. 2007; Salskov, Tammisetti et al. 2007; Solit, Santos et 
al. 2007; Yamamoto, Nishiyama et al. 2007). Compared to current diagnosis and staging 
using 2-[18F]fluoro-2-deoxy-D-glucose (18F-FDG)-PET, FLT-PET has lower sensitivity. 
But the specificity of FLT-PET for assessment of cellular proliferative activity makes it 
an ideal tracer for monitoring tumor treatment response. FLT-PET is correlated much 
better with the proliferation marker Ki67 than FDG-PET (Buck, Halter et al. 2003; 
Apisarnthanarax, Alauddin et al. 2006). FDG-PET cannot distinguish a pathologic 
complete response from residual tumor of up to 50% in correlation of post-
chemoradiation FDG standardized uptake value (SUV) and percent residual tumor in 
patients with esophageal cancer (Swisher, Erasmus et al. 2004). SUV is defined as the 
tissue concentration of tracer as measured by a PET scanner divided by the activity 
injected divided by body weight (Zasadny and Wahl 1993). Moreover FDG-PET cannot 
differentiate cancer response to radiotherapy from the local normal tissue inflammation 
caused by radiotherapy. Effective cancer treatment can occur by inducing cytostasis 
rather than cytotoxicity because cytostasis is often poorly tolerated in tumor cells and 
should lead to cell death if sustained (Rixe and Fojo 2007). Cytostatic agents stop cancer 
cells from proliferating. Clinically, cytostasis would result in SD. Many of the 
compounds now being developed are not going to lead to tumor shrinkage; the best 
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response may be SD (Herbst 2004). As an imaging marker of cellular proliferation, FLT-
PET outshines other imaging modalities in this instance. 
The early apoptotic response observed prior to tumor volume changes correlates well 
with subsequent outcome (Meyn, Stephens et al. 1995; Ellis, Smith et al. 1997; Symmans, 
Volm et al. 2000; Bremer, Ntziachristos et al. 2003). Phosphatidylserine (PS) 
externalization is one of the most widely used markers for apoptotic cell death in 
mammals. Multimodality imaging of the PS-binding protein Annexin V including 
scintigraphy, optical imaging, multispectral imaging, single-photon emission computed 
tomography (SPECT) and MRI has been used to assess apoptosis right after the initiation 
of proapoptotic therapy (Belhocine, Steinmetz et al. 2002; Schellenberger, Bogdanov et 
al. 2002; Petrovsky, Schellenberger et al. 2003; Mandl, Mari et al. 2004; Ntziachristos, 
Schellenberger et al. 2004; Dicker, Kim et al. 2005; Henery, George et al. 2008). In vivo 
imaging of apoptosis offers another noninvasive approach to monitor therapeutic 
response independent of changes in glucose metabolism or cell proliferation. Imaging 
malignant angiogenesis is also employed to evaluate treatment response, i.e., effective 
blockage of tumor vascular neoangiogenesis (Runnels, Zamiri et al. 2006; Backer, 
Levashova et al. 2007; Saxena, Gonzalez-Gomez et al. 2007; Yang, Jiang et al. 2007). 
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1.6 Figure and table 
 
Figure 1.1 TRAIL signaling pathway (Reprinted from (Falschlehner, Emmerich et al. 
2007) Copyright © 2007, Elsevier, Used by Permission) 
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Agent Mechanism Synonyms 
Apo2L/TRAIL Targeting DR4 and DR5 Dulanermin, AMG 951 
TRAIL-R1 mAb Targeting DR4 HGS-ETR1, Mapatumumab, TRM-1 
TRAIL-R2 mAb Targeting DR5 HGS-ETR2, Lexatumumab, TRM-2, 
AMG 655, CS-1008, LBY135, 
PRO95780, Drozitumab 
Table 1.1 Proapoptotic receptor agonists 
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CHAPTER 2 
Multispectral Fluorescence Imaging 
Reprinted by permission of the Society of Nuclear Medicine from: 
Zhou L and El-Deiry WS. Multispectral Fluorescence Imaging. J Nucl Med. 2009; 50(10): 
1563-1566. 
 
2.1 Abstract: Multispectral fluorescence imaging (MSFI) is a rapidly growing field 
with broad applications in both preclinical and clinical settings. Application of this novel 
technology in small animal imaging and microscopy produces enhanced sensitivity, 
reliable quantification, and resolves multiple simultaneous signals. MSFI flow cytometry 
can quantify multiple fluorescent parameters with morphological or sub-cellular spatial 
details on millions of cells. MSFI has the potential to improve the accuracy of disease 
detection/differentiation and intrasurgical metastatic diagnosis, guide neurosurgeries, and 
monitor treatment response. 
 
Key Words: multispectral fluorescence imaging, multiplexing, spectral unmixing, small 
animal imaging, microscopy, flow cytometry 
 
Multispectral imaging (MSI) is the synergistic combination of imaging and spectroscopy. 
Color is the appearance of a light most affected by wavelength () and the observers’ 
visual system. Objects with similar colors are not necessarily the same. The simplest 
example is the spectrally pure yellow and the mixture of red and green, which have 
completely different spectral content but precisely the same red-green-blue (RGB) 
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coordinates (Bearman and Levenson 2003). Spectroscopy is the technique of breaking 
light down into its composite colors to identify the object’s composition. Distinguished 
from conventional RGB full-color imaging, MSI can obtain a high resolution optical 
spectrum for each image pixel, resulting in a series of images of the same field of view 
that are acquired at different wavelengths. These can be stacked in three dimensional 
datasets or a “cube” (x, y, ). After proper calibration, quantitative images of individual 
analytes can be generated.  
There are excellent reviews of MSI instrumentation and data analysis (Hiraoka, Shimi et 
al. 2002; Bearman and Levenson 2003). Briefly, a camera is used to acquire the spatial 
information and the spectral information is gained by scanning a dispersive element to 
record spectra for each image. Electronic tunable filters such as acousto-optic tunable 
filter (AOTF) and liquid crystal tunable filters (LCTFs) are preferable to mechanically 
scanning dispersive devices (filter wheels, monochromators) because they are quiet, fast, 
compact and stable, and demonstrate increased spectral selectivity, spectral purity and 
flexibility. The disadvantages of electronic tunable filters include low light throughput, 
photobleaching and inappropriate capture if significant sample or camera movement 
occurs during the acquisition, or if high temporal resolution is needed to capture certain 
events (e.g., calcium signaling transients) (Levenson and Mansfield 2006). The typical 
method for data analysis of MSI is a least-squares fitting linear unmixing approach with 
additional constraints (such as non-negativity), resulting component images and a final 
composite image. This approach is limited to spectral analysis only whereas combining 
the rich spatial information in the images with the spectral data is a more powerful and 
evolving field (Bearman and Levenson 2003). MSFI coupled with microscopy and flow 
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cytometry are commercially available now (Zuba-Surma, Kucia et al. 2007; Mansfield, 
Hoyt et al. 2008).  
MSI technologies have been widely used in the fields of astronomy, geology, agriculture, 
industry and forensics (Hiraoka, Shimi et al. 2002; Bearman and Levenson 2003). With 
the vast development of filters, detectors, data analysis techniques, interdisciplinary 
approaches and fluorescent dyes, MSFI is a rapidly growing field with applications in cell 
biology, preclinical drug development and clinical pathology. Combining Multispectral 
fluorescence imaging (MSFI)  with small animal imaging and microscopy produces 
enhanced sensitivity, reliable quantitation, and resolved multiple simultaneous signals 
(Mansfield, Gossage et al. 2005; Levenson and Mansfield 2006). MSFI is particularly 
useful for analyzing objects that have multiple fluorescent labels that may have similar 
RGB color or that may be localized in the same or spatially overlapping compartments; 
this modality is also effective for evaluating objects that have strong whole-animal 
autofluorescence (Figure 2.1) (Levenson, Lynch et al. 2008; Mansfield, Hoyt et al. 2008; 
van der Loos 2008). Here we review a selection of preclinical and clinical studies 
describing the use of MSFI applications. 
2.2 Preclinical application of multispectral fluorescence imaging 
2.2.1 To assess tumor vascularization and monitor the antiangiogenic therapeutic 
response 
Previous studies imaged tumor angiogenesis with fluorescent proteins (Hoffman 2004; 
Hoffman 2009). MSFI provides a powerful, non-invasive means by which to assess 
tumor vascularity and to monitor the response to anti-angiogenic therapy. For example, in 
mice treated with sunitinib, a near infrared dye labeled monoclonal antibody-based probe 
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targeting VEGFR2 was imaged in vivo using a LCTF-based Maestro MSFI system (CRI 
Inc., Woburn, MA). Tumor fluorescence intensity was quantified and normalized after 
autofluorescence removal. This study demonstrates that MSFI provides rapid, non-
invasive and longitudinal assessment of the efficacy of novel angiogenesis-directed 
therapies in preclinical models of cancer (Virostko, Xie et al. 2009). To overcome 
constraints associated with exogenously administered vascular imaging probes such as 
high cost, toxicity, inconsistent delivery, differential bioavailability among animals and 
high tumor accumulation resulting from vessel leakiness, a novel method to 
noninvasively image tumor vascularization in fluorescent tumors without exogenous 
imaging probes was introduced. LCTF-based Maestro and Nuance systems (CRI Inc., 
Woburn, MA) were used for in vivo MSFI to study the biology of tumor angiogenesis and 
to monitor the effects of antiangiogenic therapies with bevacizumab. In a mouse model 
bearing tumors expressing red fluorescent protein (RFP), the spectral fluorescence 
signatures of vascular and avascular components allow for the tumor vasculature to be 
imaged and quantified without contrast agents (Figure 2.2). This technique provides real-
time imaging of tumor vascularization and monitoring the antiangiogenic therapeutic 
response in mice without the concerns specific to an exogenously administered probe 
(Mayes, Dicker et al. 2008).  
2.2.2 To generate region-selective brain maps of vascularized brain parenchyma 
A FITC-derivatized tomato lectin - based molecular imaging probe was utilized to 
generate region-selective brain maps of vascularized brain parenchyma ex vivo in rats and 
rabbits with the Maestro system. Images were unmixed to get rid of brain tissue 
autofluorescence and resolve arterial blood and specific imaging probe fluorescence 
25 
signal. After further refinement of imaging probes and metrics, this novel preoperative 
endovascular brain mapping approach may facilitate neurosurgical guidance and 
therefore improve clinical outcomes after neurosurgical resections (Manning, Shay et al. 
2009). 
2.2.3 Automatable analysis of multiplexed immunolabeled samples  
More than six markers can be quickly differentiated from each other and from 
autofluorescence using MSFI thereby allowing for the localization of multiple probes and 
avoid the need for serial sections. For example, Mansfield et al. performed six-marker 
analyses in one sample with MSFI. Quantitative and marker-specific image data were 
presented for integrative system biological studies. The drawbacks of this approach are 
too much work to prepare a series of controls of all of the combinations of markers and 
the method is less optimal for membrane or cytoplasmic marker analyses (Mansfield, 
Hoyt et al. 2008).  
2.2.4 To differentiate tissue type and provide cellular level diagnostic information  
The slit-scan confocal microendoscope uses a catheter based on a fiber optic imaging 
bundle. This multispectral system uses a prism as a dispersive element to collect a full 
multispectral image with spectral resolution of 2.9 nm at 500 nm and 8.4 nm at 750 nm. 
Human ovary and esophagus and mouse peritoneal wall and liver stained with acridine 
orange and rat intestine tagged with DiA (4-Di-16-ASP, 4-(4-(dihexadecylamino)styryl)-
N-methylpyridinium iodine, Invitrogen) were imaged ex vivo. This method of MSFI can 
distinguish tissue types and acquire high quality images. It is minimally invasive and has 
potential to provide cellular level in vivo diagnostic information as a clinical diagnostic 
instrument (Makhlouf, Gmitro et al. 2008). 
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2.2.5 Combining multispectral fluorescence imaging with quantum dots (MSFI-QDs)  
QDs are novel nanocrystal fluorophores with constant broad excitation spectra, sharp and 
symmetrical tunable emission spectra, improved brightness, superior photostability and 
simultaneous excitation of multiple fluorescence colors. QDs have been successfully 
applied in various imaging applications for in vitro diagnostics and in vivo imaging 
because of these unique optical properties. MSFI-QDs can efficiently remove background 
and precisely delineate weak spectral signatures to present ultrasensitive and multiplexed 
imaging of molecular targets in vivo (Gao, Cui et al. 2004; Su, Zhang et al. 2008). Full 
reviews on MSFI-QDs in multiplexed immunohistochemistry and in situ hybridization 
(ISH) are available (Tholouli, Sweeney et al. 2008; Xing and Rao 2008). Another use of 
MSFI-QDs is as a feasible substitute for microarray analysis. In this instance, multiplexed 
QD-labeled oligonucleotide probes can be used for ISH in human biopsies. This 
technique was tested in a study in which single and multiplexed QD-ISH was performed 
in samples with acute leukemia and follicular lymphoma. Spectral unmixing enables the 
separation of spatially colocalized signals. MSFI-QDs allow quantitative characterization 
of multiple gene expression thereby making it useful for the analysis of processed human 
clinical tissues (Tholouli, Hoyland et al. 2006). MSFI-QDs were also tested using 
streptavidin-conjugated QDs to detect up to seven signals in tonsil and lymphoid tissue. 
Slides were analyzed using confocal laser scanning microscopy. Five streptavidin-
conjugated QDs were used on the same tissue section and could be analyzed 
simultaneously on routinely processed sections (Figure 2.3). This multiplexing method 
has the potential to uncover the clinically relevant multidimensional cellular interactions 
that underlie diseases (Fountaine, Wincovitch et al. 2006). 
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2.3 Clinical application of multispectral fluorescence imaging  
2.3.1 Combining MSFI with two-photon excitation (TPE) to detect cutaneous tumors  
TPE fluorescence microscopy offers high spatial resolution, deep penetration and low 
photodamage. To detect cutaneous tumors, combined TPE and MSFI system (MTPE) 
was employed to identify different intrinsically fluorescent molecules (NADH 
(nicotinamide adenine dinucleotide), tryptophan, keratins, melanin, elastin, 
cholecalciferol and others). This technique provides functional information correlated 
with tissue structure in physiological and pathological states. MTPE is effective in 
differentiating healthy skin from basal cell carcinoma (De Giorgi, Massi et al. 2009). As 
more samples are analyzed, it should be possible to differentiate between different types 
of malignancies as well. 
2.3.2 Application of multispectral imaging flow cytometry  
MSI flow cytometry can quantify multiple fluorescent parameters with morphological or 
sub-cellular spatial details on millions of cells (For reviews see references (Zuba-Surma, 
Kucia et al. 2007; McGrath, Bushnell et al. 2008)). Nuclear translocation of NFB 
initiates the transcription of host defense related critical genes. To quantitatively measure 
the translocation of signaling molecules from the cytoplasm to the nucleus in cells, cells 
were stained with FITC-conjugated anti-NFB and 7-AAD (DNA stain) and imaged by 
flow cytometry. A similarity score that quantifies the correlation of the spatial 
distribution of the stained, translocating signaling molecule with nuclear staining was 
generated for each cell using Pearson's correlation coefficients to assess the nuclear 
translocation. This approach represents an advance over conventional microscopy or 
biochemical fractionation and western blotting for high throughput single cell or 
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subpopulation analysis (George, Fanning et al. 2006; George, Morrissey et al. 2009). MSI 
flow cytometry can not only distinguish live cells from cells in the early or late phases of 
apoptosis or from necrotic cells, (George, Basiji et al. 2004) but also accurately quantitate 
apoptosis based on morphological characterization and allow more complete and robust 
analysis of apoptosis than conventional microscopy (Henery, George et al. 2008). 
Covalent deposition of C3 fragments (C3b/iC3b) on cells is closely associated with cell-
bound chimeric humanized anti-CD20 mAb Rituximab (RTX). To quantitatively analyze 
co-localization of C3 with RTX, Raji cells were stained with fluorescently-labeled RTX 
and mAbs specific for C3b/iC3b, and then imaged in flow and analyzed for co-
localization of fluorescent probes. Analysis verified that the majority of deposited 
C3b/iC3b is co-localized with bound RTX (Beum, Lindorfer et al. 2006). 
2.3.3 Autofluorescence (AF) analysis in MSFI 
MSFI of oral tissue AF in vivo with a four channel multispectral digital microscope can 
improve detection of oral neoplasia. Decreased blue/green AF and increased red AF in 
lesions were observed in patients with histologically confirmed neoplasia (Roblyer, 
Richards-Kortum et al. 2008). MSFI of the ocular fundus AF may differentiate age 
related macular degeneration (AMD) and diabetic retinopathy (RD). AF in AMD patients 
was dominated by the red emission while RD green-shifted. Lipofuscin is the dominant 
fluorophore in the red channel. The green shift in RD may be related to increased 
advanced glycation end product concentrations (Hammer, Konigsdorffer et al. 2008). 
MSFI of sentinel lymph node AF during surgery can provide a rapid method to determine 
whether a tumor has metastasized to help determine follow up treatment. For example, to 
evaluate lymph nodes in colorectal and gastric tumors, AF microspectroscopy and MSI 
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AF microscopy have been used to analyze the AF emission of metastatic lymph node 
sections. The AF pattern and the emission spectrum of metastatic lymph nodes can 
distinguish them from the normal ones (Pantalone, Andreoli et al. 2007). MSFI of AF has 
potential for detecting oral neoplasia, discriminating fundus autofluorescence 
fluorophores and intrasurgical diagnosis of metastatic lymph nodes. 
2.3.4 Spatial-spectral analysis in MSFI 
Using exclusive spectral information from a LCTF-based MSFI system with image 
analysis software (Environment for Visualizing Images, ENVI) can identify malignant 
urothelial cells in urine cytology specimens with a sensitivity and specificity of 82% and 
81%, respectively or combined sensitivity and specificity of 73% (Jaganath, Angeletti et 
al. 2004). To increase the accuracy and specificity of the diagnosis and follow-up of 
bladder cancer, the spatial-spectral features of multispectral image stacks acquired with 
the same MSFI system were analyzed using GENetic Imagery Exploitation (GENIE) 
package (Los Alamos National Laboratory). GENIE showed a combined sensitivity and 
specificity of 85 and 95% in samples from two separate institutes. Furthermore, GENIE 
showed efficiency superior to a cytopathologist with respect to predicting the follow-up 
results (Angeletti, Harvey et al. 2005). MSFI of fine-needle aspirations (FNAs) of 
follicular adenoma and parathyroid adenoma with the Nuance system and spatial-spectral 
analysis with CRI-MLS software can differentiate and classify morphologically similar 
lesions. The best spatial-spectral imaging solution has a sensitivity of 98.5%, a specificity 
of 96.1% and a positive predictive value of 98.6% (Mansoor, Zalles et al. 2008). Spatial-
spectral analysis is a promising tool for improving detection of bladder carcinoma when 
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morphology is not enough for a definitive diagnosis and differentiation of lesions with 
subtle cytomorphologic differences. 
We have reviewed how MSFI can increase sensitivity and reliable quantification in 
preclinical and clinical applications. MSFI has been widely used in applications ranging 
from flow cytometry, microscopy, endoscopy, small animal imaging to human imaging. 
With the development of imaging devices, data analysis technologies and fluorescent 
dyes, MSFI has the potential to improve the accuracy of disease diagnosis and predict 
treatment response. 
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2.4 Figures and legends 
 
Figure 2.1 Five-color spectrally unmixed quantum dot detection of lymphatic system 
anatomy. (A) A schematic illustration of 5-color quantum dot lymphatic injection sites 
and draining destinations of spectral fluorescence imaging, with a graph of the emission 
spectra of each of the quantum dots used. Five primary draining lymph nodes were 
simultaneously visualized with different colors as shown: autofluorescence image of 
mouse (B); composite pseudo-colored detection of draining lymph nodes after spectral 
unmixing (C); image merge of the left and center panels (D). Reflectance (E) and 
spectrally unmixed and pseudo-colored image (F) of surgically dissected lymph nodes 
arranged in the same geometry as in the intact mouse. (This figure originally appeared in 
an article by Richard M. Levenson et al. in ILAR Journal 49(1). (Levenson, Lynch et al. 
2008) It is reprinted with permission from the ILAR Journal, Institute for Laboratory 
Animal Research, The National Academies, Washington DC www.national-
academies.org/ilar). 
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Figure 2.2 Noninvasive imaging of tumor vasculature using multispectral unmixing 
in fluorescent tumors. (A) The spectral fluorescent signatures of vascular components 
(emission wavelength maximum or peak emission [Emmax]=620 nm, red spectra) and 
avascular components (Emmax=610 nm, green spectra). (B) An image of a fluorescent 
tumor taken using the CRi Nuance camera attached to an AZ100 dissecting microscope 
from Nikon. (C) A high magnification image of the same tumor area as (B) showing the 
ability to detect capillaries (5–10 μm in diameter) within fluorescent tumors using 
multispectral unmixing. (D) Multispectral unmixing of a macroscopic whole body image 
of a mouse with fluorescent tumors on both rear flanks (left panel). Enlarged image of the 
left rear flank tumor (right panel). (E) Using the CRi software, a custom-threshold region 
of interest (ROI) is created in the vascular and avascular component images. A vascular 
index is then calculated by dividing the avascular component total area (mm2) by the 
vascular component total area (mm2). (Reprinted from  (Mayes, Dicker et al. 2008) © 
2008 BioTechniques, Used by Permission) 
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Figure 2.3 Quintuplet streptavidin-conjugated quantum dots multiplex and emission 
fingerprint of the multiplexed quantum dots (germinal center outlined with dotted 
line). (a) DAPI nuclear counter stain 450 nm (white). (b) CD 20 streptavidin-conjugated 
quantum dot 525 nm (red). (c) IgD streptavidin-conjugated quantum dot 565 nm (cyan). 
(d) MIB-1 streptavidin-conjugated quantum dot 605 nm (green). (e) CD 3 streptavidin-
conjugated quantum dot 655 nm (yellow). (f) CD 68 streptavidin-conjugated quantum dot 
705 nm (white). (g) Overlay of (b–f) including IgD (cyan) and CD20 (red) coexpression 
(magenta, see arrows and inset). (h) Emission profile generated from Lambda scan from 
395 to 715 nm. Dotted lines are the single emission profile from DAPI alone or each of 
the streptavidin-conjugated quantum dots alone. Solid colored lines are the indicated 
emission profiles from the Quintuplet-labeled tonsil section and gray areas define the 
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band pass filters used. Profiles with the same color indicate colocalization. Scale bar is 50 
mm. MIB-1 is a Ki-67 equivalent in formalin-fixed, paraffin-embedded tissue. (Reprinted 
by permission from Macmillan Publishers Ltd: Modern Pathology (Fountaine, 
Wincovitch et al. 2006) copyright 2006) 
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CHAPTER 3 
Significance and Specific Aims 
3.1 Significance of research 
Cancer is a major public health problem. About 1,529,560 new cancer cases are expected 
to be diagnosed and about 569,490 Americans are expected to die of cancer in 2010 
(American Cancer Society 2010). The 5-year survival from the most common cancers 
affecting people living in the United States has changed little in the last two decades 
(Ozols, Herbst et al. 2007). Although novel molecular-targeted agents made progress in 
the last decade and offer some hope in cancer treatment, clinical experience of targeted 
therapies is still at an early stage but more treatment options will be available in the 
future. PARAs are potent and selective tumor cell killers that are progressing to phase II 
clinical trials (Wiley, Schooley et al. 1995; Pitti, Marsters et al. 1996; Duiker, Mom et al. 
2006). Because of the specificity of targeted therapy, selecting the most appropriate study 
patients based on the tumoral expression of the drug target is important for disease-
directed randomized clinical studies. Otherwise these trials may fail to correctly assess 
the usefulness of a truly effective new molecularly-targeted therapy (de Bono and 
Rowinsky 2002). Either DR4 or DR5 must be present on the cell surface to transduce the 
TRAIL signal. Evaluation of tumor cell surface DR4 and DR5 expression could be 
potentially useful predictors of TRAIL sensitivity (Ashkenazi and Dixit 1998; Ashkenazi 
and Dixit 1999; Zhang, Franco et al. 1999; Kim, Fisher et al. 2000; Ozoren, Kim et al. 
2000; Ozawa, Friess et al. 2001; Shin, Kim et al. 2001; LeBlanc and Ashkenazi 2003; Jin, 
McDonald et al. 2004; Ma, Zhang et al. 2005; Khanbolooki, Nawrocki et al. 2006; 
Finnberg, Klein-Szanto et al. 2008; Grosse-Wilde, Voloshanenko et al. 2008). The 
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synergistic effect of chemotherapy in combination with TRAIL may result from 
chemotherapy-mediated increase in the expression of DR4 and DR5 (Gibson, Oyer et al. 
2000). Pre-treatment with cisplatin or taxane followed by HGS-ETR1 or HGS-ETR2 
resulted in significant higher cytotoxic effects as compared to the reverse sequence (Gong, 
Yang et al. 2006; Belyanskaya, Marti et al. 2007). Molecular imaging may be exploitable 
to optimize patient selection and sequence timing through telling how much DR4 and 
DR5 are expressed on the tumor cell surface and how long after pre-treatment DR4 and 
DR5 increased to peak. In vivo imaging can provide much more information than a tissue 
biopsy due to tumor heterogeneity and the effects of the tumor bulk and 
microenvironment in vivo. A requirement for documented presence of the target has been 
included in product labeling of about 70% of targeted oncology drugs approved by the 
FDA in recent years. So targeted oncology drugs are mainly used in patients who have 
the target in excised or biopsied tumor tissue. But the response rate is still relatively low 
(e.g. 10~14% for Avastin and Erbitux in patient with metastatic colon cancer) (Nunn 
2008). One of the explanations is the extreme heterogeneity of cancer – not only every 
patient is different but also cancers can be different even within the same patient (Shah, 
Mehra et al. 2004; Torres, Ribeiro et al. 2007). Molecular imaging holds the promise to 
dramatically improve the targeted therapy response rate by characterizing every 
primary/metastatic cancer (Nunn 2008). The presence of DR4 and DR5 on the tumor cell 
surface may not be sufficient to predict sensitivity to PARAs if TRAIL signaling is 
impaired. General therapeutic response markers will improve prediction of therapeutic 
response, especially in combination with targeted antiproliferative therapies. We 
hypothesize molecularly targeted imaging of death receptors will be efficient in 
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predicting PARA therapeutic response and that proliferation imaging may favorably 
complement the death receptor target imaging in case of an impaired TRAIL signaling 
pathway. This multimodality molecular imaging strategy will offer great opportunities for 
rational selection of targeted therapy and earlier modifications to avoid progression of a 
nonresponsive tumor (Misek, Imafuku et al. 2004; Sokolov, Nida et al. 2007). 
3.2 Specific Aims 
Cancer is the second leading cause of death in the US. As previously mentioned, cancer 
is often associated with insufficient apoptosis. An important part of the immune response 
that suppresses cancer are the apoptosis-inducing receptors including the tumor necrosis 
factor–related apoptosis-inducing ligand (TRAIL) receptors - death receptor 4 (DR4) and 
DR5 which suppresses not only cancer but also metastases. As mentioned in the 
introduction, TRAIL and DR4/DR5 agonistic monoclonal antibodies e.g. HGS-
ETR1/HGS-ETR2 as a single agent or in combined regimens in preclinical and early 
clinical trials have shown significant potential for further development. It is crucial to 
predict the sensitivity of TRAIL based treatment for individualized patient treatment in 
the age of “personalized medicine” and for selecting patients most likely to benefit from 
this kind of therapy in future clinical trials thereby speeding the drug development 
process. This is especially important because cell death defects are a major mechanism by 
which cancer evade the immune system as well as chemotherapy in general. Biomarkers 
at the level of gene transcription and gene translation are in general highly sensitive but 
require sophisticated biostatistical interpretation and tissue and/or body-fluid sampling. 
Body-fluid analyses provide only information at the time point of sampling and average 
signal of output from all lesions. Biopsies characterize only the tissues that were biopsied 
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and are prone to sampling errors in particular when analyzing tremendously 
heterogeneous cancers (Jin, McDonald et al. 2004; Shah, Mehra et al. 2004; Rudin, 
Rausch et al. 2005; Torres, Ribeiro et al. 2007). Ignoring or neglecting molecular tumor 
heterogeneity in clinical trials may fail to detect a truly effective new therapy or a 
realistic appraisal of efficacy (de Bono and Rowinsky 2002). In comparison, imaging 
approaches will yield spatially and temporally resolved information in a noninvasive 
manner. One of the major limitations in current imaging strategies is that several months 
often must go by before recognizing a failed or ineffective therapy. The overall goal of 
this dissertation is to develop efficient multimodality molecular imaging methods to 
predict proapoptotic anticancer therapy response before or at the very early stage of 
treatment. We hypothesize that the cell surface expression level of proapoptotic TRAIL 
receptors can predict the proapoptotic targeted therapeutic response following TRAIL-
receptor targeted therapy and that FLT uptake by tumor cells that correlates with cell 
proliferation can noninvasively predict proapoptotic response if the pathway is intact, and 
coupled with a significant decrease in FLT-PET tumor uptake after initiation of treatment 
might predict the anticancer therapeutic response. In order to test the validity of the 
hypothesis, the specific aims for this thesis are as follows: 
3.2.1 Aim 1. Image proapoptotic receptor agonist binding to proapoptotic 
receptors in vitro and in vivo and correlate it with proapoptotic therapeutic response.  
Aim 1.1. Characterize cancer cell lines and image the binding of TRAIL and HGS-
ETR1/2 to DR4/5 in vitro and correlate it to death induction. Evaluate DR4 and DR5 
expression level of cancer cell lines by Western Blotting and flow cytometry. Assess 
apoptosis before and after TRAIL and HGS-ETR1/2 treatment by Western Blotting, flow 
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cytometry and short-term colony assay. Label TRAIL and HGS-ETR1/2 with NIR dye 
and image binding to death receptors using different cancer cell lines. Correlate the 
binding ability of TRAIL and HGS-ETR1/2 to DR4/5 with their proapoptotic level using 
cultured cells.  
Aim 1.2. Image the binding of TRAIL and HGS-ETR1/2 to DR4/5 in vivo and correlate it 
with therapeutic response. Tumor xenografts were grown subcutaneously in 
immunodeficient mice. Labeled TRAIL and HGS-ETR1/2 were injected intravenously 
(IV). Image TRAIL and HGS-ETR1/2 binding to death receptors in vivo. Label Annexin 
V with NIR dye. Image Annexin V binding to PS on the outer plasma membrane leaflet 
of apoptotic cells shortly after treated with TRAIL. Tumors were harvested for 
immunohistochemical examinations. Correlate the binding ability of TRAIL and HGS-
ETR1/2 with their proapoptotic level in vivo.  
3.2.2 Aim 2. Image the specific marker of cellular proliferation shortly after the 
beginning of treatment with TRAIL and/or Sorafenib and correlate it to 
proapoptotic therapeutic response.  
Aim 2.1. Demonstrate non-small cell lung cancer (NSCLC) uptake of 18F-3'-fluoro-3'-
deoxy-L-thymidine (FLT) in xenograft mouse model. TRAIL and Sorafenib resistant and 
sensitive cell lines were characterized in vitro.  
Aim 2.2. Assess changes in FLT-positron emission tomography (PET) tumor uptake 
shortly after the beginning of treatment with TRAIL and/or Sorafenib and correlate with 
the tumor histological response as measured by Ki67 nuclear staining, terminal dUTP-
biotin deoxynucleotidyl transferase nick-end labeling (TUNEL) staining and H & E 
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histology, the tumor angiogenesis response by AngioSense750 near-infrared fluorescence 
imaging, and the tumor volume was measured with a caliper before and after therapy and 
tumors were weighted after excision. 
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CHAPTER 4 
Prediction of proapoptotic anticancer therapeutic response based on cell death 
target visualization and death ligand-receptor interaction 
4.1 Abstract 
Tumor growth is often associated with insufficient apoptosis. Proapoptotic targeted 
therapeutics hold great promise for treatment of many cancers. The Tumor Necrosis 
Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) and its proapoptotic receptors 
death receptor 4 (DR4) and DR5 agonistic monoclonal antibodies are being developed as 
potent targeted therapeutics because they predominantly kill cancer cells while sparing 
normal cells. A challenge to targeted therapeutics is the selection of patients who are 
most likely to benefit from targeted drugs because of the heterogeneity of cancer. 
Molecular imaging may be useful in targeted drug development by assessing the target 
expression and drug-target interaction, and predicting therapeutic response. We 
hypothesize that cell surface expression level of DR4/5 can predict the proapoptotic 
targeted therapeutic response hence visualization of proapoptotic receptors and binding of 
their agonists to proapoptotic receptors may noninvasively predict proapoptotic response 
if the pathway downstream is intact. The goal of this proof of concept study is to develop 
an optical molecular imaging strategy to predict proapoptotic anticancer therapy response 
before or at the very early stage of treatment. We labeled TRAIL and DR5 agonistic 
monoclonal antibody HGS-ETR2 (Lexatumumab, TRM-2) with a near-infrared dye and 
imaged the labeled TRAIL/HGS-ETR2 binding to its receptors on cultured human 
colorectal carcinoma HCT116 (TRAIL sensitive) and HT29 (TRAIL resistant) cells and 
non-small cell lung cancer (NSCLC) H460 (TRAIL sensitive) as well as engineered 
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H460-DR5-298 cells expressing a TRAIL decoy thereby making them TRAIL resistnant, 
and tumor xenografts derived from these cells. Imaging of cells and tumor-bearing 
animals was conducted with near infrared fluorescence imagers. Apoptosis in cells was 
assessed by western blots of PARP-cleavage and flow cytometry of subG1 content. 
Apoptosis in tumors was evaluated by imaging of near-infrared dye-labeled Annexin V 
and tumor tissue activated caspase-3 staining. Both in vitro and in vivo studies showed 
that imaging of death inducing ligand–receptor interaction was consistent with the 
apoptosis readout. Thus TRAIL sensitive tumors that express TRAIL receptors were 
predicted to undergo cell death following treatment whereas tumors lacking TRAIL 
receptor expression were shown to be TRAIL resistant. In vivo molecular imaging of 
TRAIL receptor expression correlated with response to TRAIL therapy and an apoptotic 
response in vivo. 
 
Keywords: near infrared molecular imaging; TRAIL; DR4; DR5; proapoptotic receptor 
agonists; therapeutic response 
 
4.2 Introduction 
Cancer is the second most common cause of death in the US (American Cancer Society 
2010). The 5-year relative survival rate for all cancers diagnosed between 1995 and 2001 
is 65% (Ozols, Herbst et al. 2007). Emerging targeted therapeutics offer opportunities for 
improving survival and response rates in hard-to-treat cancers. Tumor growth is often 
associated with insufficient apoptosis. The tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL), a type II transmembrane protein of tumor necrosis factor (TNF) 
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family, is one of the most powerful proapoptotic targeted biotherapeutic agents (Wiley, 
Schooley et al. 1995; Pitti, Marsters et al. 1996). TRAIL induces apoptosis in a wide 
variety of tumor cells with minimal to no effect on most normal cells. Preclinical studies 
have shown that systemic administration of TRAIL could slow the growth and, in some 
cases, induce regression of tumor xenografts and does not lead to appreciable toxicity in 
rodents or primates (Kelley and Ashkenazi 2004). Five distinct TRAIL receptors have 
been identified: death receptor 4 (DR4, TRAIL-R1) (Pan, O'Rourke et al. 1997), DR5 
(TRAIL-R2) (Walczak, Degli-Esposti et al. 1997; Wu, Burns et al. 1997), Decoy receptor 
1 (DcR1, TRAIL-R3) (Sheridan, Marsters et al. 1997), DcR2 (TRAIL-R4) (Pan, Ni et al. 
1997) and Osteoprotegerin (OPG) (Emery, McDonnell et al. 1998). DR4 and DR5 are 
type I membrane proteins containing two extracellular cysteine-rich domains (CRD) and 
a conserved cytoplasmatic death domain (DD) signaling apoptosis. The stronger 
expression of DR4 and DR5 in neoplastic cells than in normal cells accompanied by a 
higher degree of apoptosis suggests a possible functional role for these receptors in 
apoptosis induction in neoplastic colorectal cells (Koornstra, Kleibeuker et al. 2003). 
DcR1 lacks transmembrane and cytoplasmatic domains and is 
glycosylphosphatidylinositol (GPI) linked to the cell surface. DcR2 contains a truncated 
nonfunctional DD. A potential decoy function of DcR1 and DcR2 has only been observed 
in overexperssion experiments. No differences were found between tumor and normal 
cells regarding DcR1 and DcR2 expression. Experiments under physiological expression 
conditions remain to be shown (Koornstra, Kleibeuker et al. 2003). OPG is a soluble 
secreted protein also known to bind to another member of the TNF family, RANKL. OPG 
has very low affinity for TRAIL at physiological temperature. Although apoptosis 
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depends on the expression of one or both of the death domain containing receptors DR4 
and/or DR5, resistance to TRAIL-induced apoptosis does not correlate with the 
expression of the "decoy" receptors (Truneh, Sharma et al. 2000). TRAIL induces 
apoptosis through binding to proapoptotic receptors DR4 and DR5. Binding of TRAIL to 
the extracellular domain of the receptor trimer triggers the formation of the death-
inducing signaling complex (DISC) by recruiting Fas-associated death domain (FADD), 
cysteine-dependent, aspartate-specific proteases (Caspases) -8, -10 and the FLICE-
inhibitory protein (FLIP), followed by activation of caspase-8, which in type I cells leads 
to activation of caspase-3 and rapid apoptosis (extrinsic pathway). In type II cells, 
insufficient activation of caspase-8 requires amplification of the apoptotic signal through 
cleavage of the BH3-only protein Bid and activation of the intrinsic pathway to finally 
induce apoptosis. Activated Bid induces oligomerization of proapoptotic proteins Bax 
and Bak, resulting in the release of both cytochrome c and second mitochondria-derived 
activator of caspases/ direct IAP binding protein with low PI (Smac/DIABLO) from the 
mitochondria to block the caspase-3 inhibitory effect of the X-linked inhibitor of 
apoptosis proteins (XIAP) and subsequent activation of caspase 9, which leads to the 
activation of caspase 3 and subsequently apoptosis (Scaffidi, Fulda et al. 1998). For type 
II cells, blockade of the mitochondrial intrinsic pathway may render resistance of TRAIL 
(Ozoren and El-Deiry 2002). HGS-ETR1 (Mapatumumab) and HGS-ETR2 
(Lexatumumab, Human Genome Sciences) are fully humanized agonistic monoclonal 
antibodies with high affinity and specificity for DR4 and DR5 respectively. Proof of 
concept has been demonstrated that agonistic antibodies against DR4/DR5 have 
antitumor activity by inducing tumor cell death in vitro and in vivo and this killing was 
45 
mediated through the activation of both extrinsic and intrinsic pathways (Pukac, 
Kanakaraj et al. 2005; Sarantopoulos, Wakelee et al. 2005; Marini, Denzinger et al. 2006; 
Zeng, Wu et al. 2006). Just like TRAIL, DR4/DR5 agonistic antibody is a potent 
antitumor agent either used alone or in combination with other therapeutics. Moreover 
agonistic antibodies against DR4/DR5 may have enhanced therapeutic potential due to a 
prolonged half-life in vivo and the lack of binding to decoy receptors. 
Several phase I and II clinical trials have been completed or initiated with TRAIL as well 
as agonistic monoclonal antibodies against DR4/DR5 as a selective killer of tumor cells. 
TRAIL receptor targeted therapeutics as a single agent or a combined regimen in 
preclinical and early clinical trials has shown significant improvements in response rates 
and less toxicity than conventional “non-selective” cytotoxic therapies which lack 
specificity for tumor cells. But cancer is genetically diverse (Jin, McDonald et al. 2004; 
Shah, Mehra et al. 2004; Torres, Ribeiro et al. 2007). It is crucial to predict the sensitivity 
of TRAIL based treatment for individualized patient treatment in the age of “personalized 
medicine” and for selecting patients most likely to benefit from this kind of therapy 
thereby speeding the clinical trials. Selecting the most appropriate study patients for 
disease-directed randomized clinical studies is vital to ensure that the maximal usefulness 
of targeted therapies is correctly assessed. Ignoring or neglecting molecular tumor 
heterogeneity in clinical trials may fail to detect a truly effective new therapy (de Bono 
and Rowinsky 2002). Since serum analyses provide only an average signal of output from 
all lesions and biopsies characterize only the tissues that were biopsied, molecular 
imaging provides a great opportunity to characterize the tremendous heterogeneity of 
cancer. Molecular imaging is a technique that uses molecules or generates signals from 
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molecules to image specific molecular pathways in vivo, particularly those that are key 
targets in disease processes (Weissleder and Mahmood 2001). Optical imaging is 
emerging as a powerful new modality of molecular imaging to detect, diagnose, 
characterize, or monitor tumors before and after therapeutic intervention. Comparing with 
computed tomography (CT), magnetic resonance imaging (MRI), positron emission 
tomography (PET) and single-photon emission computed tomography (SPECT), optical 
imaging is real time, robust, cost-effective, rapid, easy to use, and can be readily applied 
to studying disease processes and biology in vivo. Biologic tissues are opaque to most 
wavelengths of light. Thus only small animals and structures close to the surface can be 
imaged with most visible light. However many biologic tissues are relatively transparent 
to near infrared (NIR), which enables imaging structures of 5 to 10 cm from the surface. 
Translational medical research applications of optical imaging to clinical medicine 
include the potential for breast imaging and other organs when the detection devices are 
positioned near the fluorescent probe, such as through endoscopy and intraoperative 
scanning (Shah, Gibbs et al. 2005; Cerussi, Hsiang et al. 2007; Torigian, Huang et al. 
2007; Veiseh, Gabikian et al. 2007; Luker and Luker 2008). Previous studies using Cy 
5.5-Annexin V as a NIR probe to noninvasively image tumor apoptosis in vivo post 
radiotherapy and chemotherapy demonstrated excellent fluorochrome stability and 
temporal advantage over radionuclide imaging (Reynolds, Troy et al. 1999; Petrovsky, 
Schellenberger et al. 2003).   
In this study, we show that optical molecular imaging of a therapeutic ligand and its 
target in tumor cells and xenografts could serve as a potential predictor of the 
proapoptotic treatment response. The proapoptotic receptors DR4 and DR5 must be 
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present on the cell surface to transduce the TRAIL agonist triggered apoptosis-inducing 
signal. Deficiency of DR4/DR5 expression or failed receptor trafficking to cell surface 
confers tumor cell resistance to TRAIL-induced apoptosis (Ashkenazi and Dixit 1998; 
Zhang, Franco et al. 1999; Kim, Fisher et al. 2000; Ozoren, Fisher et al. 2000; Ozoren, 
Kim et al. 2000; Jin, McDonald et al. 2004). In the screen of small interfering RNA 
(siRNA) library for genes regulating TRAIL sensitivity, the signal recognition particle 
(SRP) complex was identified and related to cell surface levels of DR4 as well as DR4-
mediated apoptosis (Ren, Wagner et al. 2004). Reintroducing wild type DR4 into DR4 
null TRAIL resisting FaDu cells leads to apoptosis and restores TRAIL sensitivity 
(Ozoren, Fisher et al. 2000). Here we show that NIR imaging of TRAIL agonists binding 
to death receptors could predict the TRAIL based therapeutic response if the pathway 
downstream is intact. This technique has important implications for improving 
predictability and efficiency of personalized treatment and for speeding drug 
development by stratifying subjects, differentiating responders from non-responders and 
informing selection of candidates for clinical testing. 
4.3 Materials and Methods 
4.3.1 Cell lines and culture 
The human colorectal carcinoma HCT116 (TRAIL sensitive) and HT29 (TRAIL resistant) 
cells and non-small cell lung cancer (NSCLC) H460 (TRAIL sensitive) cells were 
obtained from the American Type Culture Collection (ATCC). Considering artificial 
overexpression of death-domain-containing death receptors causes cell death in a ligand-
independent manner (because of the spontaneous self-aggregation of death domains when 
death receptors are expressed above physiological levels), which may interfere with the 
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assay, we designed a DR5 mutant that loses the ability to induce apoptosis after 
transfection into cells (Tschopp, Martinon et al. 1999). H460 DR5-298-EGFP cells were 
generated by inserting the open reading frame of human DR5 without the C-terminal 
death domain into pEGFP-N1 vector (Clontech) to express a fused protein with EGFP, 
transfecting the construct to H460 cells with Lipofectamine 2000 (Invitrogen) and 
selecting with G418 for 10 days. Then a cell clone with DR5-EGFP expression was 
isolated and passaged in RPMI 1640 with 10% of fetal bovine serum (FBS) and 1% 
penicillin and streptomycin (Pen/Strep). HCT116 and HT29 cells were grown in 
McCoy’s 5A media containing 10% FBS and 1% Pen/Strep. H460 and H460 DR5-298-
EGFP cells were grown in RPMI 1640 media with 10% FBS and 1% Pen/Strep at 37oC 
and 5% CO2.  
4.3.2 Production of recombinant His6-tagged soluble human TRAIL 
The extracellular portion (aa 95 281) of the human TRAIL cDNA was amplified and 
cloned into pQE80L (Qiagen) after digestion with BamHI and HindIII to generate the 
His6-tagged soluble human TRAIL expression plasmid. Recombinant His6-tagged soluble 
human TRAIL was expressed in competent E. coli DH10B cells. A single colony of 
recombinant E. coli was picked from a streaked LB agar plate supplemented with 100 
g/ml ampicillin and inoculated in 30 ml of LB broth supplemented with 100 g/ml 
ampicillin in a 250 ml flask. The culture was grown overnight (~16 hours) in a 37oC 
shaking incubator. The overnight seed culture was diluted 100-fold into 2 liter of LB 
broth with 100 g/ml ampicillin and incubated for 3 hours at 37°C in a shaking incubator. 
0.5 mM Isopropyl-1-thio--D-galactopyranoside (IPTG, Fisher Scientific) was added to 
induce recombinant protein expression, and bacterial cells were incubated for another 3 
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hours at 37°C in a shaking incubator. Cells were spun down and resuspended in 2% of 
initial culture volume binding buffer (50 mM sodium phosphate, pH 8.0, 300 mM NaCl, 
10 mM imidazole (a histidine analogue), and 10 mM -mercaptoethanol). Lysozyme was 
added at 1 mg/ml and cells were sonicated in ice and spun down to collect the supernatant.  
Ni-NTA (nickel–nitrilotriacetic acid; Qiagen) agarose beads were added to bind 
recombinant His6-tagged soluble human TRAIL. After washing with buffer containing 50 
mM imidazole, recombinant His6-tagged soluble human TRAIL was eluted with elution 
buffer containing 250 mM imidazole. The purity of the eluted protein was confirmed by 
SDS-PAGE and Coomassie Blue gel staining. Eluted protein was dialyzed against PBS. 
The concentration of the protein was checked using a Bio-Rad protein assay (Kim, Kim 
et al. 2004). 
4.3.3 Production of recombinant polyhistidine-tagged soluble Annexin V 
pProEx.Htb.Annexin V plasmid was kindly provided by Professor Seamus J. Martin at 
the Trinity College in Ireland (Brumatti, Sheridan et al. 2008). Then following the 
procedure of production of recombinant His6-tagged soluble human TRAIL to express 
and purify recombinant polyhistidine-tagged soluble Annexin V.  
4.3.4 Label TRAIL, Annexin V and HGS-ETR2 with IRDye800CW 
The IRDye800CW protein labeling kit (Low MW) was obtained from Li-Cor Biosciences. 
The labeling procedure was performed by following the manufacturer’s protocol. In brief, 
protein concentration was adjusted to 1mg/ml and the pH value was raised to 8.5 after 
buffer exchange. The protein was warmed to 20~25°C. 0.5mg of dye were dissolved in 
25 µl of ultra pure water and mixed thoroughly by vortexing. An appropriate amount of 
dye was added to the protein according to the molecular weight (MW) of the protein: Dye 
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volume (l) = 233.2/MW. The mixture was left to react for 2 hours at 20°C in the dark. 
The conjugate was separated from the free dye using a desalting column equilibrated with 
PBS. The dye/protein ratio and protein concentration were determined 
spectrophotometrically:  
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Where 0.03 is a correction factor for the absorbance of IRDye 800CW at 280 nm (equal 
to 3.0% of its absorbance at 780 nm), Dye=270,000 M-1cm-1, TRAIL=27,515 M-1cm-1, 
Annexin V=21,500 M-1cm-1, HGS-ETR2=210,000 M-1cm-1, MWTRAIL=23,000, MWAnnexin 
V=36,000, MWHGS-ETR2=143,600. TRAIL was predicted with following equation: (Pace, 
Vajdos et al. 1995) 
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4.3.5 In cell western assay with labeled TRAIL and HGS-ETR2: Cells were plated in 
96-well black plates with clear bottom and cultured to confluency. In a separate 96-well 
plate devoid of cells, 1:2 serial dilutions of IRDye 800CW labeled TRAIL and HGS-
ETR2 were prepared from well 3 to 12 and medium only was added to the first two wells. 
Media was removed from cells by inversion. 50 µl labeled protein was transferred from 
the dilutions preparing plate into the cell-containing plate quickly. Cells were incubated 
at room temperature for 5 minutes. Cells were immediately fixed by adding 150 µl of 
fresh 3.7% formaldehyde. Plate was covered with foil and incubated at room temperature 
for 20 minutes without shaking. Cells were washed four times with 200 µl of 0.1% Triton 
X-100 for 5 minutes with shaking to permeabilize the cells. 150 µl/well LI-COR Odyssey 
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blocking buffer (LI-COR Biosciences) with 0.1% Tween-20 were added and incubated 
for 1.5 hours at RT with shaking. TO-PRO-3 is a cell stain that can be used to normalize 
the signal for cell number in each well. The stain was diluted 1:5000 in LI-COR Odyssey 
Blocking Buffer. 50 µl of LI-COR Odyssey Blocking Buffer + 0.1% Tween-20 was 
added to Wells 1 and 2. These wells served as controls for any potential background due 
to the stain. 50 µL of diluted TO-PRO-3 were added to well 2 to 12 and cells were 
incubated for 1 hour with shaking. Cells were washed four times with 0.1% Tween-20 for 
5 minutes at room temperature. The plate was scanned simultaneously at 700 nm and 800 
nm using the Odyssey Infrared Imaging System (LI-COR Biosciences). A medium scan 
quality, 169 µm resolution, 3.5 mm focus offset, and an intensity setting of 5 for the 700 
channel and 7 for the 800 nm channel were used. 
4.3.6 Near-infrared imaging of labeled TRAIL, HGS-ETR2 and Annexin V in 
xenografts 
Healthy female nu/nu mice aged 4−5 weeks from Charles River Breeding Laboratories 
were inoculated subcutaneously with 2 ×106 HCT116, HT29, H460 and H460 DR5-298-
EGFP cells in each flank or shoulder. Cells were suspended in 50% Matrigel® matrix 
(Fisher Scientific) in PBS. Mouse body weight and tumor dimensions were periodically 
measured. Tumor volumes were estimated using the following equation (Euhus, Hudd et 
al. 1986; Tomayko and Reynolds 1989):  
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Tumors were established for 10 days (the tumor volume of ~150mm3). Mice were 
anesthetized with an intraperitoneal (IP) injection of 2 mg ketamine/0.3 mg xylazine. One 
group of mice was treated with TRAIL (100 µg/mouse) via IV injection and 6 hours later 
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they received an IV injection of labeled Annexin V. The other two groups received IV 
injection of labeled TRAIL and labeled HGS-ETR2 without treatment. All mice were 
prescanned and postscanned from 2 minutes to 9 days after beacon injections. The imager 
used is the Pearl Impulse in vivo fluorescent imaging system (LI-COR Biosciences).  
4.3.7 Immunohistochemistry 
As described above, when HCT116, HT29, H460 and H460 DR5-298-EGFP tumors were 
established for 10 days (the tumor volume of ~150mm3), mice were treated with vehicle 
(PBS) or TRAIL (100 µg/mouse) via intravenous (IV) injection daily for 5 days 
consecutively. Mice were sacrificed and tumors were excised and weighted. Tumors were 
cut into halves and fixed with 4% paraformaldehyde solution for 24 hours, then washed 
and dehydrated in 70% ethanol. Tumors were paraffin embedded and sectioned into 5 µm 
thick slices and mounted onto slides for analysis of active caspase-3 (an in situ marker for 
apoptosis) and Ki67 (a nuclear antigen strongly correlated with active cellular 
proliferation).  
4.3.8 Western blot analysis 
As described previously (Jin, McDonald et al. 2004), cells were treated as desired, rinsed 
with PBS and lysed directly in 24-well plates by NuPAGE® LDS Sample Buffer 
(Invitrogen). Lysates were boiled for 10 minutes and then resolved by SDS-PAGE and 
polypeptides were electrophoretically transferred to polyvinylidene difluoride membranes 
(Millipore Corp.). Membranes were blocked with 10% non-fat milk for 1 hour at room 
temperature. Membranes were incubated overnight at 4oC with primary antibodies: rabbit 
anti-human DR4 (BD Biosciences), rabbit anti-human DR5 (Cell Signaling), goat anti-
human DR5 (C20) (Santa Cruz Biotechnology), rabbit anti-human PARP (Cell Signaling) 
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and mouse anti-human Ran (BD Biosciences). Membranes were washed six times for 2, 2, 
2, 5, 15, 5 minutes respectively, and incubated with species-specific secondary antibodies 
horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG (Amersham Biosciences) 
for 1 hour at room temperature. Blots were washed six times for 2, 2, 2, 5, 30, 5 minutes 
respectively, and developed by the Enhanced Chemiluminescence system (Amersham 
Biosciences). 
4.3.9 Flow Cytometric Detection of DR4/DR5 Surface Expression 
The experiments were performed as described previously (Zhang, Franco et al. 2000; Jin, 
McDonald et al. 2004). In brief, one million cells were rinsed and detached with cell 
dissociation buffer (Invitrogen). Cells were spun down and washed with 1% FBS in PBS, 
and then resuspended in 100 µl 1% FBS in PBS containing 1 µg primary antibody against 
DR4 or DR5 (Alexis Biochemicals) or a nonspecific mouse IgG1 antibody (CALTAG 
Laboratories) as a control. After staining on ice for 60 min, cells were washed once with 
1% FBS in PBS and incubated with 1µg secondary antibody Alexa Fluor® 647-R-
Phycoerythrin Goat anti-Mouse IgG (Invitrogen) at 4°C for 45 min in the dark. Cells 
were analyzed on an Epics Elite flow cytometer (Beckman Coulter).  
4.3.10 Sub-G1 DNA content analysis 
Cells were plated in 6-well plates and treated as needed. The floating cells were collected 
and the adherent cells were trypsinized. Cells were spun down and washed with 1% FBS 
in PBS, then fixed with cold 70% ethanol. After cells were spun down and washed with 
1% FBS in PBS, 0.5 ml phosphate-citric acid buffer (192 ml 0.2 M Na2HPO4+8 ml 0.1 M 
citric acid; pH 7.8) was added to elute small DNA fragments. Cells were stained with 
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50µg/ml Propidium iodide (PI, Sigma) and RNase at room temperature for 30 min and 
then analyzed on an Epics Elite flow cytometer (Beckman Coulter). 
4.3.11 Short term colony survival assay 
A total of 2×104 cells/well were seeded in 24 well plate and cultured for a week, then 
cells were treated with 0.4 g/ml TRAIL or 1 g/ml HGS-ETR1/2. After 4 hours, the 
medium was removed and cells were rinsed with 500µl PBS. 500µl of methanol was 
added to fix the cells for 15 min at room temperature. Methanol was removed and 500µl 
Coomassie Blue was added, and cells were incubated for 5 min. Cells were rinsed with 
500µl PBS and then scanned for visualization and image preservation. 
4.3.12 Statistical Analysis 
Quantitative data was analyzed, including t-test, linear regression and correlation, using 
the EXCEL Spreadsheet Data Analysis ToolPak (Microsoft Office). 
4.4 Results and Discussion 
4.4.1 TRAIL is a more powerful apoptosis inducer than agonistic monoclonal 
antibodies 
Human colorectal carcinoma cell line HCT116 and non-small cell lung cancer cell line 
H460 are sensitive to TRAIL treatment while HT29 is quite resistant to TRAIL (Ozoren 
and El-Deiry 2002; Ricci, Kim et al. 2007). We engineered H460 cells to overexpress 
truncated DR5 (aa1-298) without death-domain to avoid ligand-independent apoptosis. 
We confirmed the sensitivity of HCT116 and H460 cell lines and resistance of HT29 and 
H460-DR5-298-EGFP cell lines to TRAIL and HGS-ETR1/2 treatment with western 
blotting of cleavage of PARP (Figure 4.1B and Figure 4.9B), flow cytometry of subG1 
content (Figure 4.3) and short term colony survival assay (Figure 4.4). HCT116 cells 
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were most sensitive to TRAIL, next to HGS-ETR2 and least to HGS-ETR1 as shown in 
Figure 4.1B. H460 cells were similarly more sensitive to TRAIL than to HGS-ETR2 as 
shown in Figure 4.9B. These results support the idea that TRAIL is a more powerful 
apoptotic agent than agonistic monoclonal antibodies since TRAIL can bind to both DR4 
and DR5.  
4.4.2 TRAIL sensitive cancer cells have higher DR4 and DR5 expression on the cell 
surface as compared to TRAIL resistant HT29 cells 
Either DR4 or DR5 must be present on the cell surface in order to respond to PARA 
treatment. Earlier studies showed that tumor cell surface DR4 and DR5 expression could 
predict TRAIL sensitivity (Ashkenazi and Dixit 1998; Ashkenazi and Dixit 1999; Zhang, 
Franco et al. 1999; Kim, Fisher et al. 2000; Ozoren, Kim et al. 2000; Ozawa, Friess et al. 
2001; Shin, Kim et al. 2001; LeBlanc and Ashkenazi 2003; Jin, McDonald et al. 2004; 
Ma, Zhang et al. 2005; Khanbolooki, Nawrocki et al. 2006; Finnberg, Klein-Szanto et al. 
2008; Grosse-Wilde, Voloshanenko et al. 2008). The total and cell surface expression 
levels of DR4 and DR5 were evaluated with Western Blotting (Figure 4.1A and Figure 
4.9C) and flow cytometry (Figure 4.2). Both total and cell surface expression levels of 
DR4 and DR5 of HCT116 were more than 10 times higher than that of HT29 as shown in 
Figure 4.1A.  
4.4.3 TRAIL resistant cancer cells may have high DR4 and/or DR5 expression on 
cell surface if downstream signaling is impaired 
As shown in the schematic representation of DR5 structure (Figure 4.9A), H460-DR5-
298-EGFP cells overexpressed truncated DR5 (1-298) without death domain. H460-DR5-
298-EGFP and H460 cell lines have the same amount of full length DR5 as probed with 
56 
antibodies raised against a peptide mapping at the carboxyl terminal of human DR5 
(Figure 4.9C upper panel).  But the total DR5 expression level of H460-DR5-298-EGFP 
soared to more than 80 times higher than that of H460 when probed against residues 
surrounding cysteine 248 of isoform 1 of human DR5 (Figure 4.9C lower panel). Taken 
together these results support that overexpression of a death receptor devoid of a death 
domain has a decoy function. But this is a different story from physiological expression 
conditions – usually no differences were found between tumor and normal cells regarding 
DcR1 and DcR2 expression (Koornstra, Kleibeuker et al. 2003). Resistance to TRAIL-
induced apoptosis does not correlate with the expression of the "decoy" receptors (Truneh, 
Sharma et al. 2000). This study can partially explain why some cancer cells with 
reasonable expression of DR4 and DR5 are resistant to TRAIL induced apoptosis. 
4.4.4 DR4 and DR5 cell surface expression level can be visualized with near infrared 
dye labeled PARAs (TRAIL and agonistic monoclonal antibodies) 
Recombinant soluble human TRAIL was expressed and purified. The purity was 
confirmed with SDS–PAGE gel. Figure 4.6B is the Coomassie Blue stained SDS–PAGE 
gel of samples taken before (uninduced), or after (induced), induction of protein 
expression, supernatant after Ni-NTA agarose beads binding (Supernatant), each wash 
fraction (Wash 1, Wash 2, Wash3, Wash4) and each elution fraction (Elution 1, Elution 2, 
Elution 3, Elution 4).  The ~23 kDa TRAIL band appeared after induction of expression 
but vanished in supernatant after Ni-NTA agarose beads binding. The yield and purity 
were adequate as 200 ml culture was found to yield more than 1 milligram recombinant 
soluble human TRAIL protein apparently free from contaminating protein. 
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Recombinant soluble human TRAIL and HGS-ETR2 were labeled with IRDye 800CW. 
The absorption spectrum of IRDye 800CW labeled HGS-ETR2 (Figure 4.5 B) is 
comparable to the free dye absorption spectrum (Figure 4.5 A) – the peak falls around 
800 nm which is amenable to detection by the Odyssey and Pearl Infrared Imaging 
System 800 nm channel image.  
IRDye 800CW labeled recombinant soluble human TRAIL was checked with SDS–
PAGE gel. Figure 4.6C is the 800 nm channel image of IRDye 800CW labeled 
recombinant soluble human TRAIL SDS–PAGE gel collected by the Odyssey Infrared 
Imaging System. Besides the monomer form of TRAIL (23 KDa), there are dimer and 
even trimer forms of TRAIL (65 kDa). This is in agreement with gel filtration 
chromatography analyzed data (Kim, Kim et al. 2004). Adding a polyhistidine tag to 
TRAIL provides a simple means of isolating TRAIL from other contaminating bacterial 
proteins in a single-step affinity purification procedure. The polyhistidine tag is smaller 
than most other affinity tags (e.g.  GST or maltose-binding protein) and is thus less likely 
to interfere with the function of TRAIL (i.e., the ability to bind to DR4/5). But His6-
tagged TRAIL is not optimized for zinc content which is crucial for stability. Thus it 
tends to form insoluble aggregates that may cause apoptosis in normal cells in preclinical 
studies (Lawrence, Shahrokh et al. 2001; Kim, Kim et al. 2004). We did observe 
insoluble aggregates of His6-tagged TRAIL and increased the sodium chloride 
concentration of dialysis buffer to 300 mM to reduce insoluble aggregates. SubG1 
analysis demonstrated that labeled TRAIL and HGS-ETR2 retain their apoptosis inducing 
function (data not shown here). So the binding ability of labeled TRAIL and HGS-ETR2 
to death receptors is not compromised by conjugation. 
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To assess TRAIL receptor cell surface expression level of HCT116 and HT29 cells, in-
cell western assay was performed with IRDye 800CW labeled TRAIL. HCT116 cells 
gave a much brighter signal than HT29 cells in the 800 nm channel (Figure 4.7 A). To 
normalize well-to-well variation in cell number, TO-PRO-3 staining (specific for nuclear 
counterstaining) was scanned in the 700nm channel. The normalized binding ability of 
labeled TRAIL to HCT116 was 3 times as that to HT29 (Figure 4.7 B). To estimate DR5 
cell surface expression level of HCT116, HT29, H460 and H460-DR5-298-EGFP cells, 
IRDye 800CW labeled HGS-ETR2 was applied to an in-cell Western assay (Figure 4.8 A 
and Figure 4.10 A). The normalized binding ability of IRDye 800CW labeled HGS-ETR2 
to HCT116 was 3 times as that to HT29 while binding to H460-DR5-298-EGFP cells was 
5 times as that to H460 (Figure 4.8 B and Figure 4.10 B). These differences were not as 
prominent as observed in Western blotting (Figure 4.1 A and Figure 4.9 C) but still 
evident. The binding ability of labeled TRAIL and HGS-ETR2 to death receptors in vitro 
was strongly correlated with the cell surface death receptor expression level.  
4.4.5 PARA imaging correlation with TRAIL induced apoptosis imaging in vivo 
To image cancer cell death receptor expression level in vivo, IRDye 800CW labeled 
TRAIL and HGS-ETR2 were injected IV into HCT116, HT29, H460 and H460-DR5-
298-EGFP xenograft-bearing mice and imaged with the Pearl near-infrared imager. 
IRDye 800CW labeled HGS-ETR2 signal of HCT116 was twice as that of HT29 (Figure 
4.11 A). We observed the IRDye 800CW labeled HGS-ETR2 signal of H460-DR5-298-
EGFP was five times as that of H460 (Figure 4.13 B). The IRDye 800CW labeled TRAIL 
signal of H460-DR5-298-EGFP was three times as that of H460. (Figure 4.13 A)  In vivo 
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imaging of DR4/5 expression level was consistent with Western blotting, flow cytometry 
and in-cell western assay findings.  
Annexin V binds to phosphatidylserine (PS) on the outer plasma membrane leaflet of 
apoptotic cells and is widely used for the detection of apoptosis (Belhocine, Steinmetz et 
al. 2002; Petrovsky, Schellenberger et al. 2003; Mandl, Mari et al. 2004; Ntziachristos, 
Schellenberger et al. 2004; Dicker, Kim et al. 2005; Henery, George et al. 2008). To 
image TRAIL induced apoptosis in vivo, polyhistidine-tagged Annexin V was expressed 
and purified following the TRAIL production protocol. The purity of recombinant soluble 
polyhistidine-tagged Annexin V was confirmed with SDS-PAGE gel (Figure 4.6 A). 
Annexin V was labeled with IRDye 800CW for imaging apoptosis. HCT116, HT29, 
H460 and H460-DR5-298-EGFP xenografts bearing mice were treated with TRAIL 
intravenously. Six hours later IRDye 800CW labeled Annexin V was injected IV and the 
800 nm channel image was collected with the Pearl imager. IRDye 800CW labeled 
Annexin V signal of HCT116 was twice that of HT29 (Figure 4.11 B). The IRDye 
800CW labeled Annexin V signal of H460-DR5-298-EGFP was three times as that of 
H460 (Figure 4.13 C). In vivo image signal intensity of TRAIL induced apoptosis was 
consistent with PARP cleavage, SubG1 content and short term colony survival assay 
(Figure 4.1, 4.3, 4.4 and 4.9). 
The DR5 expression level image with IRDye 800CW labeled HGS-ETR2 (Figure 4.11 A) 
and TRAIL induced apoptosis image with IRDye 800CW labeled Annexin V (Figure 
4.11 B) of HCT116 and HT29 showed a strong positive correlation (Figure 4.11 C). By 
contrast, the DR5 expression level image with IRDye 800CW labeled HGS-ETR2 
(Figure 4.13 B) and TRAIL induced apoptosis image with IRDye 800CW labeled 
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Annexin V (Figure 4.13 C) of H460 and H460-DR5-298-EGFP showed a strong negative 
correlation (Figure 4.13 D middle and right plots). Even DR4/5 expression level image 
with more general IRDye 800CW labeled TRAIL (Figure 4.13 A) and TRAIL induced 
apoptosis image with IRDye 800CW labeled Annexin V (Figure 4.13 C) of H460 and 
H460-DR5-298-EGFP showed a strong negative correlation (Figure 4.13 D left and right 
plots). 
Of note, the Annexin V signal lasted for several days – there was still strong signal 4 days 
and even 8 days post IV injection of IRDye 800CW labeled Annexin V (Figure 4.12 A 
and B). This gives the benefit of a flexible imaging schedule.  
4.4.6 PARA imaging correlation with immunohistochemistry post TRAIL treatment 
The body weight of both TRAIL treated and control group mice bearing HCT116, HT29, 
H460 and H460 DR5-298-EGFP xenografts did not change significantly (Figure 4.14). 
This is consistent with prior reports that TRAIL is safe in both preclinical and clinical 
trials (Herbst, Mendelson et al. 2006; Ling, Herbst et al. 2006). Mouse tumor size is 
usually evaluated based on tumor dimensions measured with calipers. Comparing tumor 
volume with excised tumor weight gave very strong positive correlations (Figure 4.15). 
So we can track tumor volume to estimate tumor weight in preclinical treatment trials. 
Tumor shrinkage is one of the treatment response markers.  Comparing tumor size before 
and post TRAIL treatment, the mean values of HCT116 and H460 tumor volume were 
less than those of HT29 and H460-DR5-298-EGFP but the variations were too big so the 
differences were not significant.   
That HCT116 is sensitive to and HT29 is resistant to TRAIL induced apoptosis was 
confirmed with tumor active Caspase-3 staining (Figure 4.16). TRAIL induced extensive 
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apoptosis in HCT116 tumors but not in HT29 tumors. This result was evident with 
labeled Annexin V imaging post TRAIL treatment (Figure 4.11 B) and DR5 expression 
level imaging of HCT116 and HT29 tumors using labeled HGS-ETR2 (Figure 4.11 A). 
Optical molecular imaging that can directly assess molecular targets shows great promise 
for predicting targeted therapeutic response. On the other hand, tumor Ki67 staining 
revealed that TRAIL inhibited cellular proliferation in H460 tumors but not in H460-
DR5-298-EGFP tumors (Figure 4.17). Like labeled Annexin V imaging (Figure 4.13 C), 
this was negatively correlated with the targeted death receptor expression imaging with 
labeled TRAIL and HGS-ETR2 (Figure 4.13 A and B). Different from wild-type DR5, 
the existence or overexpression of DR5-298 did not improve TRAIL induced apoptosis 
but increased the dominant-negative effect – in this case DR5-298 inhibited TRAIL 
signaling through the DR4 receptor by competing for ligand binding (Bin, Thorburn et al. 
2007).  
4.5 Conclusion 
Emerging targeted therapeutics hold great promise for the treatment of human cancer. 
However there are numerous challenges for selecting patients who are most likely to 
benefit from targeted drugs. Molecular imaging can be useful to characterize target 
protein expression, drug-target interactions and tumor response, hence stratify patients 
with regard to the presence or absence of a drug target and provide tests to distinguish 
rapidly between responders and nonresponders to a drug. Engagement of cell surface 
death receptors by TRAIL is the initial step in the induction of intracellular death 
signaling pathways and apoptosis. DR4/DR5 is essential for TRAIL and agonist antibody 
induced apoptosis. This proof-of-concept study supports that imaging of DR4/DR5 and 
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binding of TRAIL and agonist antibodies to DR4/DR5 is feasible and can predict 
proapoptotic anticancer therapeutic response. We conclude that TRAIL imaging is safe in 
preclinical treatment trial and TRAIL is a more powerful apoptosis inducer than agonistic 
monoclonal antibodies. Cell surface DR4 and DR5 expression level was correlated with 
sensitivity to TRAIL induced apoptosis and could be imaged with near infrared dye 
labeled TRAIL and agonistic monoclonal antibodies. Both in vitro and in vivo studies 
demonstrated that imaging PARAs binding to their targets was well correlated with 
proapoptotic anticancer therapeutic response when the TRAIL signaling pathway was 
intact. Overexpression of truncated DR5 reversed H460 sensitivity to TRAIL induced 
apoptosis and turned a strong positive correlation between imaging PARAs binding to 
death receptors and PARA treatment response to a strong negative correlation. To pursue 
a more general molecular imaging marker that can predict anticancer therapeutic 
response even when the signaling pathway is impaired, we explored imaging of 
phosphatidylserine-sensing Annexin V post TRAIL treatment and demonstrated 
additional correlations between target imaging and cell death in vivo.  
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4.6 Figures and legends 
 
Figure 4.1 The correlation between death receptors DR4/5 expression levels of 
HCT116 and HT29 cells and their response to death receptor agonists TRAIL and 
HGS-ETR1/2 treatment. (A) DR4 and DR5 expression levels of HCT116 and HT29 
were determined by western blotting. Ran serves as loading control.  (B)  4 hours post-
treatment, apoptosis of HCT116 and HT29 induced by different dosage of TRAIL and 
HGS-ETR1/2 as indicated was assessed for PARP cleavage by western blotting. Ran 
serves as loading control.  
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Figure 4.2 HCT116 and HT29 cell surface expression levels of DR4 and DR5 were 
analyzed by flow cytometry. Primary antibody is control mouse IgG1 or Alexis mouse 
monoclonal antibody to human DR4 (HS101) or monoclonal antibody to human DR5 
(HS201). Secondary antibody is Alexa Fluor® 647-R-Phycoerythrin Goat anti-Mouse 
IgG (H+L). 
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Figure 4.3 SubG1 content of HCT116 and HT29 was analyzed by flow cytometry 
before and 4 hours post 50 ng/ml or 200 ng/ml TRAIL treatment.  
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Figure 4.4 Short term colony survival assay of HCT116 and HT29: 4 hours post 
treatment with 0.4 g/ml TRAIL or 1 g/ml HGS-ETR1/2 TRAIL, survival colonies of 
HCT116 and HT29 cells were stained with Coomassie Blue in 24-well culture plate.  
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Figure 4.5 The absorption spectra of IRDye 800CW (A) and IRDye 800CW labeled 
HGS-ETR2 (B). 
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Figure 4.6 Purified recombinant soluble Annexin V and TRAIL and labeled TRAIL. 
(A) SDS–PAGE gel of purified recombinant soluble Annexin V; (B) SDS–PAGE gel of 
samples taken at various stages of the process of bacterial expression and purification of 
recombinant TRAIL. Samples were taken from culture before (Uninduced), or after 
(Induced), induction of protein expression, supernatant after Ni-NTA agarose beads 
binding (Supernatant), each wash fraction (Wash 1, Wash 2, Wash3, Wash4) and each 
elution fraction (Elution 1, Elution 2, Elution 3, Elution 4).  Note the appearance of the 
~23 kDa TRAIL band after induction of expression. (C) SDS–PAGE gel of IRDye 
800CW labeled TRAIL imaged at 800 nm with the Odyssey Infrared Imaging System. 
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Figure 4.7 Imaging TRAIL receptor expression level of HCT116 and HT29 with 
IRDye 800CW labeled TRAIL using in-cell Western assay. (A) Plate setup for in-cell 
western assay and 800-channel image.  (B) Normalization using TO-PRO-3 is detected in 
the 700-channel. The graph represents normalized quantitative data demonstrating the 
differentiation of HCT116 and HT29 binding ability to TRAIL. 
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Figure 4.8 Imaging DR5 expression level of HCT116 and HT29 with IRDye 800CW 
labeled DR5 antibody HGS-ETR2 using in-cell western assay. (A) Plate setup for in-
cell western assay and 800-channel image.  (B) Normalization using TO-PRO-3 is 
detected in the 700-channel. The graph represents normalized quantitative data 
demonstrating the differentiation of HCT116 and HT29 binding ability to DR5 antibody 
HGS-ETR2. 
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Figure 4.9 The correlation between truncated DR5 expression level of H460 cells 
and their response to death receptor agonists TRAIL and HGS-ETR2. (A) Schematic 
representation of DR5 structure: H460-DR5-298-EGFP cells overexpressed truncated 
DR5 (1-298) without death domain.  (B) Apoptosis induced by TRAIL and DR5 antibody 
HGS-ETR2 was assessed for PARP cleavage by western blotting. Ran serves as loading 
control. (C) Full length DR5 and all DR5 expression levels were probed with antibodies 
raised against a peptide mapping at the carboxyl terminal of human DR5 and a peptide 
corresponding to residues surrounding cysteine 248 of isoform 1 of human DR5 
respectively. Shorter exposure signals are shown on the right. Ran serves as loading 
control.  
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Figure 4.10 Imaging TRAIL receptor expression level of H460 and H460-DR5-298-
EGFP with IRDye 800CW labeled TRAIL using in-cell western assay. (A) Plate 
setup for in-cell western assay and 800-channel image.  (B) Normalization using TO-
PRO-3 is detected in the 700-channel. The graph represents normalized quantitative data 
demonstrating the differentiation of H460 and H460-DR5-298-EGFP binding ability to 
TRAIL. 
73 
 
Figure 4.11 Imaging DR5 expression level and TRAIL induced apoptosis in vivo. (A) 
Imaging of labeled HGS-ETR2 binding to HCT116 and HT29 in vivo.  (B) Imaging of 
apoptosis induced by TRAIL with IRDye 800CW labeled Annexin V. (C) Quantitative 
comparison of DR5 expression level of (A) and TRAIL induced apoptosis (B). The 
histograms show the labeled DR5 antibody signal intensity is correlated with that of 
labeled Annexin V. 
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Figure 4.12 Imaging of apoptosis induced by TRAIL with IRDye 800CW labeled 
Annexin V on day 4 (A) and day 8 (B) post labeled Annexin V intravenous injection. 
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Figure 4.13 Imaging DR5 expression level and TRAIL induced apoptosis. (A) 
Imaging of IRDye 800CW labeled TRAIL binding to H460 and H460-DR5-298-EGFP in 
vivo. (B) Imaging of IRDye 800CW labeled DR5 antibody HGS-ETR2 binding to H460 
and H460-DR5-298-EGFP in vivo.  (C) Imaging of apoptosis induced by TRAIL with 
IRDye 800CW labeled Annexin V. (D) Quantitative comparison of labeled TRAIL signal 
intensity (A), labeled DR5 antibody HGS-ETR2 signal intensity (B) and labeled Annexin 
V signal intensity (C). The histograms show the truncated DR5 overexpressed H460-
DR5-298-EGFP has stronger binding ability to TRAIL and DR5 antibody but less 
apoptosis. 
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Figure 4.14 The body weight change of mice bearing HCT116, HT29, H460 and H460 
DR5-298-EGFP xenografts after treated with TRAIL (100µg/mouse) via IV injection 
daily for 5 days consecutively.  
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Figure 4.15 Correlation of tumor volume and tumor weight. Tumor volume of mouse 
subcutaneous tumors HCT116, HT29, H460 and H460 DR5-298-EGFP were estimated 
by measuring tumor dimensions. Excised tumors were weighted. (A) Mouse tumor 
volume and weight were plotted in the same chart. Correlation analysis reported 
Correlation Coefficient 0.888. (B) Regression analysis of mouse tumor volume and 
weight reported Coefficient of Determination 0.7879.  
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Figure 4.16 Active Caspase-3 staining of control and TRAIL treated HCT116 and 
HT29 tumors. (A) Original scan of control HCT116 tumor; (B) High-power view of 
control HCT116 tumor (original scan ×40); (C) Original scan of TRAIL treated HCT116 
tumor; (D) High-power view of TRAIL treated HCT116 tumor (original scan ×40); (E) 
Original scan of control HT29 tumor; (F) High-power view of control HT29 tumor 
(original scan ×40); (G) Original scan of TRAIL treated HT29 tumor; (H) High-power 
view of TRAIL treated HT29 tumor (original scan ×40). 
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Figure 4.17 Ki67 staining of control and TRAIL treated H460 and H460-DR5-298-
EGFP tumors. (A) Original scan of control H460 tumor; (B) High-power view of 
control H460 tumor (original scan ×40); (C) Original scan of TRAIL treated H460 tumor; 
(D) High-power view of TRAIL treated H460 tumor (original scan ×40); (E) Original 
scan of control H460-DR5-298-EGFP tumor; (F) High-power view of control H460-
DR5-298-EGFP tumor (original scan ×40); (G) Original scan of TRAIL treated H460-
DR5-298-EGFP tumor; (H) High-power view of TRAIL treated H460-DR5-298-EGFP 
tumor (original scan ×40).  
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CHAPTER 5 
FLT-PET as an early marker of therapeutic response in non-small cell lung cancer: 
the value of xenograft animal modeling in imaging clinical trial design 
This chapter was submitted to the Journal of Nuclear Medicine and co-first authored with 
Sharyn I. Katz, and co-authored with Wenge Wang, Thomas Ferrara, Patrick A. Mayes, 
Charles Smith and Wafik S. El-Deiry. 
5.1 Abstract 
Rationale: 18F-3'-fluoro-3'-deoxy-L-thymidine (18F-FLT), a novel positron emission 
tomography (PET) tracer of proliferation, is being developed as an early therapeutic 
response indicator. In this manuscript, we examine variables to be considered in assessing 
treatment-related changes in tumor uptake of FLT and discuss the role of animal 
modeling in clinical trial design. 
Materials and Methods: The sensitivities of the human non-small cell lung cancer cell 
line CALU-6 to TRAIL and Sorafenib was confirmed in vitro with cell viability assays 
and subG1 FACS analysis. Three animal trials were conducted with CALU-6 tumor-
bearing Nu/Nu Mouse (Crl:NU-Foxn1nu) xenografts with daily treatment with TRAIL 
(200 g IV)/ Sorafenib (30 mg/kg IP) therapeutic durations of 11-19 days. In the first 
trial of 8 mice, tumor changes in FLT uptake were assessed at 96 hrs of treatment. This 
experiment was repeated with 25 mice, this time using tumors too large to treat 
successfully, with changes in tumor FLT uptake assessed at 72 hrs of treatment.  Finally, 
in a trial of 30 mice, daily TRAIL/Sorafenib therapy was compared to drug vehicle and 
weekly doses of cisplatin (IP)/docetaxel (IP) with tumor treatment related changes in FLT 
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uptake measured at 72 hours. In all trials, tumor response was also assessed with external 
tumor caliper measurement and histology. 
Results: Xenografted CALU-6 tumors responded to daily combination therapy TRAIL 
IV/ Sorafenib IP as determined by tumor caliper measurements, decreased accumulation 
of AngioSense, a blood-pooling optical imaging agent, decreased Ki-67 nuclear staining, 
increased TUNEL staining and tumor hyalinization. There were significant decreases in 
tumor uptake of FLT at 72 hours of TRAIL/Sorafenib therapy. Reductions in tumor FLT 
uptake were also seen after therapy with cisplatin/docetaxel but were however were very 
modest given the changes in tumor volume and apoptosis seen at end of therapy. 
Conclusions: Early changes in FLT-PET may not only predict success of a 
chemotherapeutic regimen but also determine superiority of one treatment regimen over 
another. The timing of last dose administration of chemotherapy may affect the scale of 
the FLT response. Further trials are needed to fully assess this variable. 
Keywords: FLT, PET, response, lung, cancer 
5.2 Introduction 
Lung cancer is the leading cause of cancer-related death world-wide with 1.3 million 
deaths/year (WHO, 2009 http://www.who.int/mediacentre/factsheets/fs297/en/index.html), 
the majority of whom are diagnosed at advanced stage with less than one-year survival. 
With targeted therapy taking center stage for lung cancer therapeutics, imaging methods 
tailored to measuring changes in targeted endpoints are needed especially given that the 
currently accepted response criteria, New Response Evaluation Criteria in Solid Tumors 
RECIST 1.1. (Eisenhauer, Therasse et al. 2009) was formulated based on conventional 
therapy and imaging. For example the tyrosine kinase inhibitors (TKIs) erlotinib and 
82 
gefitinib, may manifest response with stable disease rather than with significant tumor 
regression as measured by RECIST1.1.  
Furthermore, individual patient therapy and pharmaceutical development would benefit 
greatly if imaging of therapeutic response could take place in days to weeks rather than 
months as currently done with CT.   Additionally, functional imaging agents designed to 
measure components of specific molecular pathways and targets allow for a better 
understanding of tumor biology and heterogeneity. Earlier response feedback would 
allow for an earlier switch to a more effective therapy and optimize the process of drug 
development. For all these reasons, functional imaging biomarkers of tumor response are 
now of intense interest. One such promising new biomarker of response to therapy is 18F-
3'-fluoro-3'-deoxy-L-thymidine (18F-FLT), a novel PET radiotracer and marker of tumor 
proliferation. 
FLT is an analogue of thymidine and has been validated as a marker of proliferation in 
numerous recent publications. This tracer has already shown promise (Bading and 
Shields 2008; Larson and Schoder 2009), both in animal models (Barthel, Cleij et al. 
2003; Leyton, Latigo et al. 2005; Buck, Kratochwil et al. 2007; Chao 2007; Molthoff, 
Klabbers et al. 2007; Graf, Herrmann et al. 2008; Kim, Lee et al. 2008; Debucquoy, 
Devos et al. 2009; Lawrence, Vanderhoek et al. 2009; Pantaleo, Landuzzi et al. 2009) and 
clinical trials(Sugiyama, Sakahara et al. 2004; Pio, Park et al. 2006; Chen, Delaloye et al. 
2007; Herrmann, Ott et al. 2007; Herrmann, Wieder et al. 2007; Kenny, Coombes et al. 
2007; Sohn, Yang et al. 2008; Ullrich, Zander et al. 2008; Been, Hoekstra et al. 2009; 
Brockenbrough, Morihara et al. 2009; Everitt, Hicks et al. 2009), as an early indicator of 
therapeutic response potentially as early as 24-48 hours after chemotherapeutic 
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administration. FLT is metabolized via the DNA salvage pathway and is trapped within 
the cell by phosphorylation mediated through thymidine kinase 1 (TK1). The expression 
and activity of TK1 is tightly regulated by cell cycle control mechanisms (Hu and Chang 
2007; Ke, Hu et al. 2007; Brockenbrough, Morihara et al. 2009; Munch-Petersen 2009). 
Since thymidine is not a component of RNA, the FLT trapped and concentrated in the 
cell reflects the product of DNA synthesis only, although FLT is not actually 
incorporated into the DNA as are other thymidine analogues such as tritiated thymidine. 
A challenge to emerging chemotherapy for lung cancer is the prevalence of resistance to 
tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), an innate 
stimulator of programmed cell death, either at the onset or during the course of therapy. 
In an earlier publication from our laboratory we described the sensitization of TRAIL 
resistant human cancer cell lines CALU-6 and HT29 following pre-incubation with the 
multi-targeted tyrosine kinase inhibitor, Sorafenib, in vitro and in vivo, an effect mediated 
via suppression of MCL-1L and c-IAP2 (Ricci, Kim et al. 2007).  Both TRAIL pathway 
therapeutics (Spierings, de Vries et al. 2003; Voortman, Resende et al. 2007; Greco, 
Bonomi et al. 2008; Stegehuis, de Wilt et al. 2010), primarily explored via proapoptotic 
receptor agonists (PARAs) and Sorafenib (Carter, Chen et al. 2007; Gridelli, Maione et al. 
2007; Blumenschein, Gatzemeier et al. 2009; Takezawa, Okamoto et al. 2009) have 
demonstrated potential in the management of non-small cell lung cancer primarily as part 
of a multi-drug regimen. In particular, Sorafenib has been very promising in a growing 
number of malignancies and is currently FDA approved for unresectable hepatocellular 
carcinoma and renal malignancy. 
84 
With the proliferation of potential therapeutic drug combinations, an efficient means to 
triage drug efficacy would be invaluable not only for selection of drug therapies for a 
particular tumor phenotype but also to expedite the discovery process. In this chapter, we 
evaluate a validated xenograft mouse model of non-small cell lung cancer as a tool for 
comparing drug therapy regimens employing emerging imaging agents of drug response.  
Cisplatin and docetaxel combination therapy, a conventional regimen for treatment of 
lung cancer, was compared to combination therapy with TRAIL and Sorafenib. 
Correlation was made between early changes in tumor uptake of FLT-PET and 
morphologic tumor response to therapy, assessed with external tumor caliper 
measurement and histology. The optical imaging agent AngioSense (Montet, 
Ntziachristos et al. 2005; Binstadt, Patel et al. 2006; Kelly, Waterman et al. 2006), which 
is a blood pooling agent and thus a measure of tumor vascularity, was also explored as a 
specific endpoint to targeted therapy with Sorafenib. 
5.3 Materials and Methods 
5.3.1 Cell lines and cell culture: The human cell line utilized for in vitro studies was 
CALU-6 which was newly purchased from American Type Culture Collection (ATCC, 
Manasas, VA). Care was taken to limit the number of passages to less than 20 to avoid 
inadvertent in vitro selection. When not in use, cells were stored in liquid nitrogen in 
10% DMSO/ 90% culture medium. 
Cells were maintained in a humidified sterile environment with 5% CO2, 37oC RPMI 
medium supplemented with 10% heat-inactivated fetal calf serum with 1% penicillin and 
streptomycin (CM). Passage of cell lines was performed at 1:5 dilution after detachment 
using sterile 0.5% trypsin-EDTA solution. 
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5.3.2 Chemotherapeutics: Flag-TRAIL was synthesized via plasmid expression and 
purification and stored as a 1 mg/ml stock in dPBS at -20oC. Sorafenib was synthesized 
in powder, free base form for use in our laboratory. Sorafenib was dissolved in 100% 
DSMO and stored at -20oC as a concentrated stock for in vitro studies. Sorafenib was 
dissolved in a Cremaphor EL solution (Sigma-Aldrich, St. Louis, MO), made freshly for 
each daily dose for in vivo studies. Cisplatin powder was purchased from (Sigma-Aldrich, 
St. Loius, MO) and prepared freshly in dPBS prior to each injection. Docetaxel 10 mg/ml 
solution was obtained from the University of Pennsylvania Abramson Cancer Center 
pharmacy and diluted in a 13% EtOH solution. 
5.3.3 In vitro cell death assays: Cells were harvested from culture with 0.5% trypsin-
EDTA and washed with the CM then plated at 0.6  106/well in a sterile 6-well plate. 
Cells were then incubated at 37oC, 5% CO2 for 18-24 hours to allow attachment of cells 
to the wells.  Sorafenib (diluted in CM from 32mM stock in DMSO) was then added to 
the appropriate wells for a total of 4 ml CM and cells were allowed to incubate with 
Sorafenib for 16-22 hours. For comparison, cells were also treated for 4 hours of TRAIL 
therapy with and without pre-incubation with Sorafenib, Flag-TRAIL (diluted in CM 
from a 1 mg/ml stock) was added to the appropriate wells at either 50 ng/ml or 100 ng/ml.  
Culture medium for wells, not containing Sorafenib, was treated with 0.1% DMSO to 
control for the possible effects of DMSO on cell viability. After incubations with the 
chemotherapeutics, cells were washed with cold sterile dPBS then fixed with 10% 
methanol/10% acetic acid solution for 10 minutes. These fixed adherent cells were then 
stained with 2 ml of 0.25% Coomassie Blue solution for 3 minutes followed by gentle 
rinse with distilled water and then allowed to air-dry. 
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5.3.4 Propidium Iodide FACS: After incubations with chemotherapeutics in a 60 mm 
tissue culture dish, supernatants and adherent cells were removed from the dish surface 
using 0.5% trypsin-EDTA, and washed with 5ml cold dPBS. Cell pellets were then 
resuspended in 5 ml cold 75% EtOH and allowed to fix from overnight to 1 month at 4oC. 
On the day prior to FACS analysis, the EtOH was removed and cells were washed with 
5ml cold dPBS, permeabilized with 0.5ml phosphate-citric acid buffer. (192ml 0.2M 
Na2HPO4+8ml 0.1M citric acid; pH should be ~7.8) for 5 minutes, then resuspended in 
~300l PBS/FBS/PI/RNase solution (300l 1PBS /1%FBS+30l 0.5mg/ml PI+5.5l 
USB RNase) and allowed to incubate overnight at 4oC. The cells were then sorted by 
FACS the next day and the subG1 fraction measured.  
5.3.5 Xenograft formation Prior to the use of animal models, protocol approval was 
obtained by the IACUC at the University of Pennsylvania.  2 month old female Nu/Nu 
mice (Crl:NU-Foxn1nu) (Charles River Laboratory) were injected subcutaneously in each 
flank with 2  106 cells suspended in a 50% sterile, endotoxin-free Matrigel solution. 
After therapy/imaging completion, mice were euthanized with an intraperitoneal injection 
of 6 mg ketamine/0.9 mg xylazine followed by cervical dislocation. 
5.3.6 In vivo therapeutic trials: Following xenograft formation, FLT-PET or FDG-
PET was performed prior to initiation of chemotherapy.  Sorafenib was administered at a 
dose of 30 mg/kg diluted in a Cremaphor EL/13% EtOH vehicle solution and injected IP 
daily for 11-19 days. TRAIL was diluted in PBS and injected by tail vein at 100 
µg/mouse daily. Cisplatin was diluted in PBS vehicle and injected IP at 3mg/kg daily. 
Docetaxel was obtained freshly diluted from the Abramson Cancer Center pharmacy in a 
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13% ETOH vehicle solution and injected IP at 7.5 mg/kg daily. Both cisplatin and 
docetaxel were dosed weekly. 
A total of three in vivo trials were conducted in order to assess the dynamics of FLT-PET 
uptake in several therapeutic settings (Figure 5.1). The first trial was a pilot study of 8 
CALU-6 tumor-bearing xenografted mice, half of which received TRAIL/Sorafenib 
therapy for 15 days and the other 4 were untreated (no vehicle). FLT-PET imaging was 
performed, along with micro CT, just prior to therapy initiation and at day 4 of daily 
therapy. A period of 24 hours was allowed without chemotherapy prior to FLT-PET in 
order to avoid drug-drug interactions.   
Before euthanasia, all mice were imaged with the AngioSense (VisEn Medical, Inc., 
Bedford, MA) optical imaging agent, a specific marker for angiogenesis. 
The second trial was a cohort of 24 CALU-6 tumor-bearing mice divided into 2 groups, 
half of which received TRAIL/Sorafenib and the other received no treatment (no vehicle). 
The tumors were allowed to grow to approximately 300 mm3 prior to therapy in order to 
assess changes in FLT-PET uptake in a tumor sensitive to therapy but refractory to 
successful treatment due to size. These mice received TRAIL/Sorafenib daily in the 
manner described above for a total of 2 weeks. FLT-PET was performed before and at 3 
days of daily therapy. A period of 24 hours was allowed without chemotherapy prior to 
FLT-PET in order to avoid drug-drug interactions. After euthanasia, tumors were excised 
and preserved for histology in a 4% para-formaldehyde solution.  
Finally, in the 3rd trial, tumors were allowed to grow to 200 mm3 to ensure large enough 
tumors to image. A total of 25 mice were employed in this cohort, 8 in the 
TRAIL/Sorafenib group, 8 in the cisplatin/docetaxel group, 5 in no treatment/no imaging 
88 
group, and 4 in vehicle only group (2 in Cremaphor EL vs 2 in PBS). In this trial, 
TRAIL/Sorafenib, which was dosed daily, was given 1 hour prior to beginning the FLT-
PET imaging session. Cisplatin/docetaxel, which was dosed weekly, was given 3 days 
prior to the post-therapy FLT imaging. 
5.3.7 PET imaging and image interpretation: Tumors were allowed to grow until 
they reached 150-200 mm3 by caliper measurements utilizing the formula 
2
2
1 widthlengtheTumorVolum  . FLT and FDG radiotracers were synthesized in the 
in the PET Cyclotron Facility at the University of Pennsylvania. After anesthesia with 
inhaled isoflurane in O2 (3% induction, 1.5% maintenance), mice were injected with 200-
250 mCi of FLT or FDG then allowed to recover from the anesthesia and given a 60 
minute uptake time to allow radiotracer to accumulate in the tumor. At 60 minutes, the 
mice were again anesthetized and imaged for a 15 min static acquisition on the small 
animal PET scanner (A-PET, built in collaboration with Philips Medical Systems) located 
at the University of Pennsylvania. This system has very high spatial resolution (approx 2 
mm), operates exclusively as a fully 3D instrument with very high sensitivity and large 
field-of-view of 12 cm in both axial and transverse directions. Images were reconstructed 
with the manufacturer software and tumor volumes of FLT and FDG were quantitated 
with the freely available Amide 3D software (Amide’s a Medical Image Data Examiner 
(AMIDE), LG Software Innovations), which allows for multiplanar analysis of the tumor 
volume for ROI (region of interest) placement and statistical data analysis including the 
mean and max standardized uptake value (SUV) for FLT and FDG in the assigned ROI.  
5.3.8 Optical imaging: At 48 hours prior to sacrifice during experiment 1, each mouse 
was injected with 100 mg of AngioSense 750 IV by tail vein and a time course of 
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imaging (pre, 20 minutes, 6 hours, 24 hours and 48 hours) was acquired on the Maestro 
multispectral imaging system (CRI, Woburn MA), with the deep red filter set (excitation: 
670-710nm; acquisition mono: 780nm; acquisition cube: 730 to 900nm), with mice 
anesthetized with an intraperitoneal injection of 2 mg ketamine/0.3 mg xylazine. The 
AngioSense signal was measured and unmixed from background autofluorescence using 
the CRI post-processing software. Immediately after euthanasia, the tumors were excised 
and AngioSense signal measured directly from the tumor on the IVIS system using ICG 
filter set (excitation: 710-760 nm; emission: 810-875 nm). 
5.3.9 Histological Analysis After euthanasia, tumors were promptly excised, weighed 
and immersed in a 4% paraformaldehyde solution and allowed to incubate overnight at 
4oC. The tissues were then removed and placed in a solution of 70% ethanol for from 24 
hours to 2 weeks, maintained at 4oC until paraffin embedding, sectioned into 5 mm thick 
slices and mounted onto slides. Slides were stained for Ki67, a nuclear antigen strongly 
correlated with active cellular proliferation, and the terminal deoxynucleotidyl transferase 
dUTP nick end labeling (TUNEL), a method for detecting DNA fragmentation generated 
during apoptosis by labeling the terminal end of nucleic acids. 
5.3.10 Statistical Analysis: Quantitative data was analyzed, including T-test, linear 
regression and correlation, using the EXCEL Spreadsheet Data ToolPak (Microsoft 
Office). 
5.4 RESULTS 
The human non-small cell lung cancer line CALU-6 is sensitive to Sorafenib and TRAIL 
combination therapy in vitro and in vivo.  To establish a xenograft model of the spectrum 
of therapeutic response in human lung cancer, we explored whether CALU-6 cells 
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demonstrate TRAIL resistance and synergistic response to therapy with TRAIL/Sorafenib 
both in vitro, as previously observed (Ricci, Kim et al. 2007), and in vivo. CALU-6 is a 
commercially available human non-small cell lung cancer line previously characterized 
as TRAIL resistant and modestly sensitive to Sorafenib. We again demonstrated TRAIL 
resistance, modest sensitivity to Sorafenib and synergistic, dose-dependent cell killing 
achieved with combination Sorafenib/TRAIL best accomplished with Sorafenib 
pretreatment followed by the addition of TRAIL. CALU-6 sensitivities were confirmed 
using brightfield microscopy (Figure 5.2), subG1 FACS analysis by propidium iodide 
staining and cell killing assays with Coomassie blue stain. 
5.4.1 FLT-PET is a sensitive predictor of response of tumor to therapy at 72 hours 
of treatment. 18F-FLT uptake by CALU-6 was validated by FLT-PET/CT imaging of a 
xenograft mouse at 60 minutes post 209µCi FLT IV injection (Figure 5.3). With CALU-6 
response to TRAIL/Sorafenib therapy established in vitro, we then examined CALU-6 
tumor response to therapy with TRAIL/Sorafenib in an Nu/Nu Mouse (Crl:NU-Foxn1nu) 
model. In addition, we assessed changes in tumor accumulation of FLT at 72-96 hours of 
combination therapy with TRAIL and Sorafenib in order to explore changes in FLT 
uptake as a predictor of tumor morphological and histological response to therapy. In 
order to explore the sensitivity of FLT-PET to detect actual tumor response to therapy, 
rather than only inherent tumor cell sensitivity to the TRAIL/Sorafenib regimen, changes 
in tumor accumulation of FLT were also examined in the setting of failure of CALU-6 
xenograft tumor treatment with TRAIL/Sorafenib accomplished by starting therapy with 
xenograft tumors that were too large to treat successfully. 
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In the first in vivo experiment, the changes in tumor accumulation of FLT observed at 96 
hours of daily TRAIL/Sorafenib therapy were correlated with changes in tumor volume 
and histology measured at the termination of therapy. The tumor volume change over the 
15 day treatment period was 52% (TRAIL/Sorafenib) and 206% (untreated) respectively 
and was predicted by the change in the max SUV for FLT (FLTmax) at 96 hours of 
therapy, -17% (TRAIL/Sorafenib) versus 9% (untreated) respectively (p=0.05) (Figure 
5.4). Changes in the mean SUV for FLT (FLTmean) for treated and control groups did 
not reach statistical significance. Since Sorafenib has known anti-angiogenic activity, 
tumor response to therapy was also assessed, at the completion of the therapy, with the 
optical imaging with AngioSense, a blood-pooling agent. As expected, there was a 
marked decrease in tumor accumulation of AngioSense in the TRAIL/Sorafenib 
treatment group relative to the untreated controls (Figure 5.5).  
In the second in vivo trial, changes in FLT uptake at 72 hours correctly predicted the 
failure of large CALU-6 tumors to respond to therapy with TRAIL/Sorafenib, despite the 
known inherent sensitivity of CALU-6 to TRAIL/Sorafenib therapy. The faster growth of 
the treatment group relative to the control (544% versus 314%) was attributed to 
allocation of larger tumors to the treatment group to avoid early termination of the 
experiment due to IACUC regulations. Increase in tumor accumulation of FLT at 72 
hours of treatment was correlated with failure of the treatment regimen as determined by 
overall tumor change and histological response after 19 days of TRAIL/Sorafenib daily 
therapy. The average change in tumor FLTmax for control versus treated was -7% vs. 
10% (p= 0.11) respectively (Figure 5.4). FDG-PET was not able to predict the failure of 
TRAIL/Sorafenib therapy in this trial. The average change in the max SUV for FDG 
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(FDGmax) for control versus treated was -20% and -10% respectively. These results 
again demonstrate that early changes in FLT uptake are sensitive to therapeutic efficacy 
and may outperform FDG-PET for this purpose.  
5.4.2 Differential early changes in FLT-PET uptake predicted superiority of 
TRAIL/Sorafenib regimen over cisplatin/docetaxel in CALU-6 tumor-bearing 
xenograft mice. We also wished to explore whether early changes in tumor accumulation 
of FLT was sensitive to relative chemotherapeutic efficacy and therefore able to 
distinguish responses between two therapies. In the 3rd trial of TRAIL/Sorafenib therapy, 
a total of 25 mice were studied in the following groups: no treatment/no imaging (n=5), 
vehicle only (Cremaphor EL, n=2 vs PBS, n=2), TRAIL/Sorafenib (n=8) and 
cisplatin/docetaxel (n=8). Five mice were neither treated nor given the vehicle or imaged 
so as to provide a normal tumor growth trajectory for comparison. After 2 weeks of daily 
therapy with TRAIL/Sorafenib, changes in tumor volume and histology revealed that 
daily TRAIL/Sorafenib therapy was more effective at slowing tumor growth compared to 
cisplatin/docetaxel. This differential tumor therapeutic response was predicted by 
changes in tumor uptake of FLT at 72 hours (Figure 5.4 and 5.6). TRAIL/Sorafenib 
therapy resulted in a slowed tumor growth relative to the untreated group (21% vs.104%, 
p=0.00001) and vehicle Cremaphor EL group (21% vs. 53%, p=0.06) which was 
predicted by a significant drop in tumor accumulation of FLTmax (-30% and -17% for 
TRAIL/Sorafenib and vehicle Cremaphor EL respectively) (Figure 5.4). The treatment 
effect exerted by the Cremaphor EL vehicle, (53% growth versus 104%) for the vehicle 
Cremaphor EL and untreated groups respectively (p=0.02) was predicted by the decrease 
in FLTmax uptake (-17%) relative to baseline at 72 hours (Figure 5.4).  
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Cisplatin/docetaxel therapy resulted in a slowed tumor growth relative to the untreated 
group (54% vs.104%, p=0.008) and vehicle PBS group (54% vs. 143%, p=0.01) which 
was discordant with tumor accumulation of FLTmax (-2% and -12% for 
cisplatin/docetaxel and vehicle PBS respectively) (Figure 5.4). While the 
TRAIL/Sorafenib therapeutic group did show more marked slowing of tumor growth 
than the cisplatin/docetaxel group (21% vs. 54%, p=0.02), both groups demonstrated 
efficacy which was underestimated by change in tumor FLTmax accumulation in the 
cisplatin/docetaxel group. The FLTmean changes were correlated with the terminal 
changes of tumor volume as plotted in Figure 5.7. 
While changes in tumor accumulation of FDG-PET at 72 hours was predictive of 
therapeutic efficacy of cisplatin/docetaxel and TRAIL/Sorafenib, FDG-PET was not able 
to discriminate between the relative efficacies of the 2 treatment groups or detect the anti-
tumor effect of the Cremaphor EL vehicle. 
5.4.3 Optical imaging with AngioSense demonstrated decreased vascularity of 
tumors associated with Sorafenib therapy. A major endpoint of targeted therapy with 
Sorafenib is angiogenesis. AngioSense, a near-infrared optical blood pooling imaging 
agent, preferentially accumulated in the vascular spaces of the CALU-6 xenograft tumors 
and demonstrated significantly less avidity for tumors treated with Sorafenib/TRAIL. 
This provides another measure of response detection in animal models of malignancy 
when studied for endpoints of anti-angiogenic therapy. The signal from AngioSense was 
imaged optimally at 48 hours after contrast administration. The decreased vascularity of 
the TRAIL/Sorafenib treated tumors was also easily identified ex vivo in white light and 
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with near infrared AngioSense signaling, allowing correlation without tumor 
repositioning (Figure 5.5).  
5.5 DISCUSSION 
In this study, we explored the sensitivity of early changes in FLT-PET to predict 
therapeutic efficacy in a xenograft model of non-small cell lung cancer (NSCLC). While 
they are imperfect models of human disease, murine xenograft models of malignancy 
provide a vehicle for exploration of the variables that impact FLT-PET imaging in the 
therapeutic setting. We chose a targeted therapeutic combination, TRAIL/Sorafenib, 
since such agents represent an area of intense drug development and are yet to be fully 
characterized with respect to therapeutic response measurement. TRAIL/Sorafenib, is a 
novel combination for lung cancer; however, both drugs are independently in clinical 
trials to assess efficacy in NSCLC (Spierings, de Vries et al. 2003; Voortman, Resende et 
al. 2007; Blumenschein 2008; Blumenschein, Gatzemeier et al. 2009; Stegehuis, de Wilt 
et al. 2010).  Finally the use of TRAIL and Sorafenib in this mouse model of lung cancer 
produces a spectrum of response since CALU-6 is TRAIL resistant, modestly responsive 
to Sorafenib monotherapy and demonstrates a pronounced response with combination 
therapy (Ricci, Kim et al. 2007; Kim, Ricci et al. 2008).  
For this study we began by confirming the sensitivity profile of CALU-6 first in vitro and 
then in vivo using CALU-6 grafted Nu/Nu (Crl:NU-Foxn1nu) female mice. These mice 
demonstrated sufficiently low endogenous levels of thymidine to allow for FLT-PET 
analysis, a factor which can complicate the use of mouse models for FLT imaging 
(Mankoff, Shields et al. 2005). Daily TRAIL/Sorafenib therapy yielded significant 
decreases in tumor volume and increased apoptosis. This morphologic evidence of 
95 
therapeutic response to TRAIL/Sorafenib therapy strongly correlated with significant 
decreases in tumor uptake of FLT-PET 4 days post the initiation of daily therapy (Figure 
5.4 and 5.6). 
Once CALU-6 tumor responsiveness to TRAIL/Sorafenib was established in vivo, the 
sensitivity of FLT-PET to therapeutic efficacy was explored. First, since larger tumors 
are known to interfere with successful therapeutic response in mouse models, the size of 
the tumor volumes at the start of therapy was doubled to 300-350 mm3.  Despite the 
intrinsic sensitivity of CALU-6 to TRAIL/Sorafenib, these large tumors did not respond 
to daily TRAIL/Sorafenib therapy (Figure 5.4). This lack of response was correctly 
predicted by FLT-PET at 72 hrs of daily therapy and confirmed with end of trial tumor 
volumes and histology. The rate of growth was higher than expected in the treated group, 
likely a result of larger tumors being allocated to this group to avoid early termination. 
This was done to ensure that both groups would remain viable for the duration of the 
experiment, and not sacrificed prematurely due to institutional IACUC regulations 
regarding allowed tumor growth.  Since the goal of this experiment was to evaluate early 
FLT-PET responses to suboptimal therapy, rather than proving therapeutic efficacy of 
TRAIL/Sorafenib, this was not felt to be a significant confounder. 
Finally, the efficacy of two therapeutic regimens was conducted in order to examine the 
sensitivity of changes in tumor accumulation of FLT to superiority of one effective 
regimen over another. A total of 25 mice bearing subcutaneous CALU-6 tumors were 
allocated to therapy with TRAIL/Sorafenib, cisplatin/docetaxel or a control group (Figure 
5.5). CALU-6 sensitivity to cisplatin/docetaxel therapy in cell culture and xenograft 
models has been well established in the literature (Schiller and Bittner 1999; Strawn, 
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Kabbinavar et al. 2000; Teicher, Chen et al. 2000; Teicher, Forler et al. 2000; 
Miknyoczki, Jones-Bolin et al. 2003; Gourdeau, Leblond et al. 2004; Davies, Logie et al. 
2007) and the therapeutic dosage and schedule was chosen accordingly. As expected, 
TRAIL/Sorafenib daily therapy resulted in slowed tumor growth, increased apoptosis and 
evidence of tumor necrosis which was again predicted by changes in tumor uptake of 
FLT-PET at 72 hrs of daily therapy (Figure 5.4). The accepted in vivo vehicle for 
Sorafenib, Cremaphor EL, demonstrated anti-tumor effects, a known intrinsic property 
(ten Tije, Verweij et al. 2003) of this vehicle. These anti-tumor effects included decreased 
tumor uptake of FLT-PET, slowed tumor growth and increased tumor apoptosis. The 
antitumor effects of Cremaphor EL vehicle alone was modest relative to that of 
TRAIL/Sorafenib, and while this may confound assessment of therapeutic efficacy of 
TRAIL/Sorafenib, it was interesting that changes in tumor uptake of FLT accumulation at 
72 hrs could discriminate between the untreated, vehicle and TRAIL/Sorafenib treatment 
groups (Figure 5.4). 
The major caveat to the conclusions from these series of studies was that the lack of 
significant change in FLT-PET tumor uptake in the cisplatin/docetaxel treatment group 
despite a moderate treatment effect evidenced by decreased tumor volumes and increased 
tumor apoptosis relative to controls. It is likely that this discordance between early FLT-
imaging and morphological/histological response in the cisplatin/docetaxel treatment 
group is attributable to pharmacological properties of the drugs themselves resulting in 
differing drug half-life, dosing schedule, and bioavailability. We hypothesize that the 
timing of the dosing schedule relative to FLT imaging was responsible for the lack of 
observed effect of cisplatin/docetaxel on tumoral FLT uptake. The TRAIL/Sorafenib 
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group was dosed daily with a dose delivered 1-3 hours prior to post-treatment FLT-PET. 
Cisplatin/docetaxel was dosed weekly with the last dose delivered 3 days prior to post-
therapeutic FLT-imaging. This 3 day delay prior to imaging that may be responsible for 
the inadequate effect on the post-treatment tumor accumulation of FLT. TK1, which 
phosphorylates and traps FLT in the cell, has fluctuating expression and activity which is 
tightly regulated by the cell cycle (Hu and Chang 2007). This dynamic response of 
proliferation, which includes chemotherapeutic insult, has been documented, although not 
studied in the setting of FLT-PET imaging. A systematic evaluation the relationship of 
chemotherapeutic pharmacokinetics and tumor proliferation is therefore needed.  
Thus while robust clinical trials are ultimately needed to fully characterize drug efficacy, 
animal models are still valuable in the early stages of therapeutic development. The use 
of FLT in evaluation of drug efficacy allows for serial assessment of impact of therapy on 
tumor proliferation, comparison of tumor proliferation with changes in targets of therapy, 
and may allow use of more than one drug, drug combination or drug dosage to be 
examined within the same animal cohort.   
5.6 CONCLUSION 
In summary we have demonstrated that early changes in tumor uptake of FLT-PET are 
not only predictive of tumor sensitivity to a chemotherapeutic regimen, but also to subtle 
differences in tumor responsiveness either due to ineffective therapy or superiority of one 
effective treatment regimen over another. Our results highlight the need for further 
characterization of the relationship between therapeutic drug half-life and time of 
measurement of tumor accumulation of FLT. 
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5.7 Figures and legends 
  
Figure 5.1 Algorithms for the three treatment/imaging trials: (A) Pilot comparison of 
FLT uptake before and 4 days after combination therapy with TRAIL/Sorafenib. (B) 
Evaluation of the impact of increased tumor size on FLT as a predictor of response to 
therapy in a drug combination known to have efficacy with CALU-6.  
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Figure 5.1 Algorithms for the three treatment/imaging trials: (C) Comparison of 
TRAIL/Sorafenib and cisplatin/docetaxel, 2 therapy regimens that have efficacy and the 
ability of changes in tumor uptake of FLT-PET to predict response to therapy 
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Figure 5.2 Brightfield microscopy images of CALU-6 demonstrate sensitivities to 
TRAIL and Sorafenib. CALU-6 demonstrated resistance to TRAIL, modest sensitivity 
to Sorafenib and synergistic cell killing with combination therapy with TRAIL and 
Sorafenib. 
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Figure 5.3 FLT-PET/CT of Lung Cancer Xenografts. FLT-PET/CT was taken at 60 
minutes post 209µCi FLT IV injection. 
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Figure 5.4 FLT is accumulated by CALU-6 mouse xenograft tumors at differing 
rates, depending on the therapy administered. (a) Daily TRAIL/Sorafenib therapy for 
96 hours resulted in a marked drop in FLTmax tumor accumulation relative to untreated 
controls. (b) FLTmax response to TRAIL/Sorafenib therapy was not observed at 72 hours 
after daily therapy in mice with xenograft tumors too large to treat successfully. (c) Daily 
TRAIL/Sorafenib therapy for 72 hours resulted in an expected marked decrease in tumor 
accumulation of FLTmax relative to controls. The Cremaphor EL vehicle also 
demonstrated some anti-tumor activity as expected (d) Tumor FLTmax response at 72 
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hours after 1st weekly dose cisplatin/docetaxel did not demonstrate a response to therapy 
relative to controls. 
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Figure 5.5 Treatment of CALU-6 xenografts with daily TRAIL/Sorafenib for 15 
days resulted in a robust therapeutic response as measured by morphological and 
histological measures. (a, e) Optical imaging with blood pooling agent AngioSense 
demonstrated marked decreased intratumoral vascularity after TRAIL/Sorafenib but not 
in the untreated group (b, f). Tumor excision following sacrifice revealed smaller, 
smoother, paler tumors in the TRAIL/Sorafenib group (c.) compared to untreated (d.). 
Post-treatment morphological changes correlated with histological markers of response 
including a robust increase in apoptosis as measured by TUNEL staining (green), in the 
treated (g) relative to untreated tumors (h). Blue nuclear staining represents DAPI 
counterstain. AngioSense in vivo signals were quantified (i). 
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Figure 5.6 Tumor FLT-PET imaging revealed response to therapy at 72 hours after 
treatment initiation. FLT-PET demontstrated marked suppression of tumor proliferation 
72 hours after daily TRAIL/Sorafenib therapy but little response 72 hours after 
cisplatin/docetaxel therapy which is dosed weekly. Timing of drug dosing relative to 
FLT-PET imaging may affect scale detectable change in tumoral accumulation of FLT. 
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Figure 5.7 Xenograft uptake changes of FLT-PET predicted response to therapy at 
3 Days. Liner regression of change in FLTmean uptake versus changes in tumor volume 
revealed significant correlations between FLTmean and changes in tumor volume.  
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CHAPTER 6 
Summary and Future Work 
6.1 Summary 
Increased understanding of cancer biology has led to the development of promising 
targeted therapies tailored to perturb cancer-specific pathways. Inducing apoptosis and 
inhibiting proliferation are two of most effective ways to treat cancer. TRAIL based 
proapoptotic receptor agonists and the multikinase inhibitor Sorafenib studied in this 
dissertation are prime examples of targeted therapies - targeting apoptosis and 
proliferation respectively. Targeted therapeutics have shown great promise in early 
studies but did not produce the expected miraculous results in the clinic come out even 
though most patients had documented presence of the target in excised or biopsied tumor 
tissue. The main culprit is the extreme heterogeneity of cancer.  
In this dissertation optical molecular imaging was exploited to assess DR4 and DR5 
expression on the tumor cell surface. We found that DR4/5 cell surface expression level 
can be visualized with near infrared dye labeled TRAIL and DR4/5 agonistic monoclonal 
antibodies HGS-ETR1/2 in vitro and in vivo. Imaging of DR4/5 expression level is 
correlated with TRAIL induced apoptosis as confirmed with Western blotting of PARP 
cleavage, flow cytometry of subG1 DNA content, short term colony survival assay and 
active caspase-3 staining of tumor tissue section. TRAIL induced apoptosis can be 
imaged with near infrared dye labeled Annexin V in vivo.  Images of cell surface DR4/5 
expression are correlated with those of TRAIL induced apoptosis. But this correlation 
breaks down when TRAIL signaling is impaired. Engineered H460-DR5-298-EGFP cells 
have truncated DR5 overexpressed on cell surface but are resistant to TRAIL induced 
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apoptosis for lack of death domain. This further proved that labeled PARA imaging 
reported the DR4/5 levels on cell surface instead of the total expression levels. This 
proof-of-concept study supports that imaging of DR4/DR5 and binding of TRAIL and 
agonist antibodies to DR4/DR5 is feasible and can predict proapoptotic anticancer 
therapeutic response if TRAIL signaling is intact. The strategy we developed in this work 
for optical molecular imaging of therapeutic targets in vitro and in vivo with near infrared 
fluorescent dye labeled therapeutic agent can be extended to studies of other targeted 
therapeutics. Imaging apoptosis directly with phosphatidylserine-sensing Annexin V at 6 
hour post TRAIL treatment is a complementary strategy that can correct the misleading 
information from truncated DR5. 
In addition we explored FLT-PET as a more general molecular imaging marker of 
cellular proliferation to predict therapeutic response at the beginning of anticancer 
treatment, especially when combining with antiproliferation therapeutics such as 
Sorafenib. We found that FLT-PET is a sensitive predictor of the response of tumors to 
therapy at 72 hours of treatment. Differential early changes in FLT-PET uptake predicted 
the superiority of TRAIL/Sorafenib regimen over cisplatin/docetaxel in CALU-6 tumor-
bearing xenograft mice. Taken together, early changes in tumor uptake of FLT-PET are 
not only predictive of tumor sensitivity to a chemotherapeutic regimen, but also to subtle 
differences in tumor responsiveness either due to ineffective therapy or superiority of one 
effective treatment regimen over another. Optical imaging with AngioSense 
demonstrated decreased vascularity of tumors associated with Sorafenib therapy.  
Some minor contributions of this work include strategies to successfully produce and 
label recombinant soluble TRAIL and Annexin V. TRAIL imaging is safe in preclinical 
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treatment trial and is more powerful to induce apoptosis than DR4/5 agonistic 
monoclonal antibodies HGS-ETR1/2. Sorafenib synergizes with TRAIL to induce more 
prominent apoptosis than single agent therapy and cisplatin/docetaxel in non-small cell 
lung cancer Calu-6. 
In summary multimodality molecular imaging will greatly aid in accelerating targeted 
anticancer drug approval process and improving survival and response rates in hard-to-
treat cancers. 
6.2  Future work 
Imaging cancer DR4/5 expression with near infrared fluorescent dye labeled TRAIL and 
HGS-ETR1/2 was able to assess cancer cell surface DR4/5 expression level accurately 
but cannot predict resistance caused by impaired downstream signaling. Complementary 
imaging of downstream apoptotic markers such as active caspase-3 and 
phosphatidylserine (imaging with IRDye 800 CW labeled Annexin V shown in this work) 
can offset mutant DR4/5 misleading information. Future work on this project would 
follow the directions listed below.  
1. Checking other tumor xenografts with a broad range of receptor expression. The 
current study demonstrated the feasibility of predicting anticancer therapeutic response 
with death receptor imaging and FLT uptake changes in a few sensitive and resistant 
tumor xenograft models. Further evaluation in larger study populations with a broad 
range of receptor expression is warranted.  
2. Checking the impact of decoys by using the HGS-ETR1/2. TRAIL imaging shows the 
expression level of both proapoptotic receptors and antiapoptotic receptors. HGS-ETR1/2 
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imaging shows only proapoptotic receptors. The impact of decoy receptors on TRAIL 
sensitivity could be assessed by comparing TRAIL imaging with HGS-ETR1/2 imaging.  
3. Combining the death receptor imaging with FLT-PET imaging to predict response 
prospectively. Basing on normalized death receptor imaging intensity and FLT 
standardized uptake value (SUV) change, a TRAIL response index can be derived for 
prediction of response to TRAIL induced apoptosis.  
4. Improving death receptor imaging sensitivity. In the current study, TRAIL treatment 
dosage in cell culture is nM but in-cell Western assay is mM. To improve sensitivity, we 
can improve detection sensitivity (in vitro from plate scan to slide scan; in vivo from 
animal imager to macroscope, e.g. Nuance) and optimize binding ability (adjust 
Dye/Protein).  
5. In the long run, isotopic labeling of TRAIL and HGS-ETR1/2 may be possible for 
clinical trial. Tracer dosage of TRAIL and HGS-ETR1/2 will be sufficient for PET 
imaging. The decay period of 18F is short (less than 24 hours) so it is feasible to do two 
PETs to predict the TRAIL treatment response. 
6. Early changes in Calu-6 tumor uptake of 18F-FLT are not only predictive of tumor 
sensitivity to a chemotherapeutic regimen, but also to subtle differences in tumor 
responsiveness either due to ineffective therapy or superiority of one effective treatment 
regimen over another. Future work of this project would be further characterization of the 
relationship between therapeutic drug half-life and time of measurement of tumor 
accumulation of 18F-FLT.  
7. The principal assumptions for the use of 18F-FLT uptake as a surrogate of proliferation 
are that the tumor utilizes thymidine salvage to a significant degree and that the therapy 
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induces cell cycle regulation of TK1. If the tumor relies predominately or completely on 
de novo nucleoside synthesis or has defective p53 response (common in tumor cells), 18F-
FLT uptake won’t report on proliferation status correctly. In the future, to extend FLT-
PET results from Calu-6 to other cell lines, validating these two assumptions is essential.  
8. In future cell membrane fluorescence labeling can be added to current work. 
Preliminary results are presented in Figure 6.1. The CellVue® Maroon is a lipophilic 
membrane intercalating fluorescent dye with long aliphatic tails (Horan and Slezak 1989). 
We can label MSTO-211H mesothelioma cell membrane with CellVue® Maroon and 
inject labeled cells to nu/nu mice subcutaneously or intraperitoneally. After treated with 
Sorafenib at 64 mg/kg daily for 3 weeks, mice were imaged with the Maestro imaging 
system. A significant response of mesothelioma to Sorafenib therapy is shown in Figure 
6.1 – the treated mouse had markedly less gross tumor burden and marked cell death on 
histology. CellVue Maroon can identify both subcutaneous and intraperitoneal xenograft 
tumor cell mass. (Figure 6.1 E and F)  
9. Molecular imaging of protein kinases, important regulators of signal-transduction 
pathways and related to more than 400 human diseases, will greatly facilitate targeted 
anticancer drug development. (Zhang, Lee et al. 2007; Zhang, Bhojani et al. 2008; Chan, 
Paulmurugan et al. 2009) We planned to develop an ERK1/2 reporter basing on 
conformation dependent complementation of firefly luciferase to test inhibition of ERK 
phosphorylation in vivo for our ongoing studies with Sorafenib and TRAIL receptor 
targeting agents. Dr. Alnawaz Rehemtulla from the University of Michigan kindly 
provided plasmids, ERK(wt) and MBP(wt), and cell lines, BxPC3-ERK(wt) and BxPC3-
MBP(wt), and the domain structure and action mechanism diagram of the 
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Bioluminescence ERK reporters (Figure 6.2 A and B). We treated BxPC3-MBP(wt) cells 
with TRAIL and Sorafenib and imaged with IVIS system. Figure 6.2 D suggests that 
Sorafenib inhibited ERK1/2 activity at the concentration of 64 M. 
10. Recently the O-glycosylation of TRAIL proapoptotic receptors was discovered to 
facilitate receptor clustering and caspase-8 activation in tumor cells. Comparing amino 
acid sequence of DR4/5 predicted conserved extracellular O-glycosylation sites. O-linked 
glycans regulate functional properties of DR4/5 including their conformation, trafficking 
and turnover. In vitro sensitivity to PARAs is strongly predicted by the expression of the 
O-glycosylation initiator enzyme N-acetylgalactosaminyltransferase-14 (GALNT14) in 
non–small cell lung cancer (NSCLC) and other cancer cell lines, and of the 
fucosyltransferase (FUT) enzymes, FUT3 and FUT6 in colorectal cancer (CRC) cell lines 
(Wagner, Punnoose et al. 2007). Immunohistochemistry (IHC) assays were developed to 
measure GALNT14 and FUT3/6 levels in formalin-fixed, paraffin-embedded human 
NSCLC and CRC tissue (Stern, Padilla et al. 2010). GALNT14 and FUT3/6 could be 
potential molecular imaging markers for non-invasively predicting response or resistance 
to PARA treatment in vivo.  
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Figure 6.1 Pilot evaluation of human MPM cell lines in a xenograft mouse models 
suggests Sorafenib efficacy. nu/nu mice were injected IP with human malignant pleural 
mesothelioma cell line, MSTO-211H cell surface labeled with a fluorescent label, 
CellVue Maroon. Images above demonstrate (A) untreated (3 weeks daily IP vehicle) (B) 
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treated with Sorafenib 60 mg/kg daily for 3 weeks (C) exposed untreated tumor with 
peritoneum resected (D) exposed treated tumor with peritoneum resected (E) large soft 
tissue IP tumors (F) and smaller tumor lesions demonstrate fluorescence in the expected 
excitation/absorption spectrum for CellVue Maroon cell surface labeled MSTO-211H 
utilized for these IP injected tumors. Immediately after sacrifice, xenografted tumor 
tissues were dissected, fixed in 4% formalin, paraffin-embedded, sectioned in 6 m slices 
and stained with hematoxylin and eosin. Treated tumor nodules demonstrated marked 
hyalinization and reduce tumor viability (H) compared with untreated tumor (G). 
This work was previously published in Cancer Biology and Therapy: Sharyn I. Katz*, 
LanLan Zhou*(*equal contribution), Grace Chao, Charles D. Smith, Thomas Ferrara, 
Wenge Wang, David T. Dicker, Wafik S. El-Deiry. Sorafenib inhibits ERK1/2 and MCL-
1L phosphorylation levels resulting in caspase-independent cell death in malignant pleural 
mesothelioma. Cancer Biology and Therapy. 2009 Dec; 8(24):2406-16. Epub 2009 Dec 2. 
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Figure 6.2 Bioluminescence MEK reporters: (A) The domain structure of the 
Bioluminescence ERK reporters. Two versions of the Bioluminescence ERK reporters 
were developed: the ERK(wt) molecule, which contains a specific sequence in ERK1/2 
that MEK phosphorylates; and the MBP(wt) molecule, which contains the MBP target 
sequence that is phosphorylated by ERK1/2. (B) The proposed mechanism of action for 
the Bioluminescence ERK reporters involves MEK-dependent phosphorylation of the 
ERK/MBP domain, which results in its interaction with the Phospho-peptide binding 
domain (left). In this form, the reporter has minimal bioluminescence activity. In the 
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absence of MEK activity, the N-Luc and C-Luc domains reassociate, restoring 
bioluminescence activity (right). (C) BxPC3 cells expressing MBP(wt) reporter were 
treated with TRAIL (100 ng/mL), Sorafenib (64 μM) and Sorafenib (8 μM) and imaged 
with IVIS system.  
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